

RESEARCH ARTICLE

Open Access

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in *BRCA1* and *BRCA2* mutation carriers

Karoline B Kuchenbaecker^{1*}, Susan L Neuhausen², Mark Robson³, Daniel Barrowdale¹, Lesley McGuffog¹, Anna Marie Mulligan^{4,5}, Irene L Andrulis^{6,7}, Amanda B Spurdle⁸, Marjanka K Schmidt⁹, Rita K Schmutzler^{10,12}, Christoph Engel¹³, Barbara Wappenschmidt^{10,11,14}, Heli Nevanlinna¹⁵, Mads Thomassen¹⁶, Melissa Southey¹⁷, Paolo Radice¹⁸, Susan J Ramus¹⁹, Susan M Domchek²⁰, Katherine L Nathanson²⁰, Andrew Lee¹, Sue Healey²¹, Robert L Nussbaum²², Timothy R Rebbeck²³, Banu K Arun²⁴, Paul James^{25,26}, Beth Y Karlan²⁷, Jenny Lester²⁷, Ilana Cass²⁷, Breast Cancer Family Registry²⁸, Mary Beth Terry²⁹, Mary B Daly³⁰, David E Goldgar³¹, Saundra S Buys³², Ramunas Janavicius^{33,34}, Laima Tihomirova³⁵, Nadine Tung³⁶, Cecilia M Dorfling³⁷, Elizabeth J van Rensburg³⁷, Linda Steele², Thomas v O Hansen³⁸, Bent Ejlersen³⁹, Anne-Marie Gerdes⁴⁰, Finn C Nielsen³⁸, Joe Dennis¹, Julie Cunningham^{41,42}, Steven Hart⁴², Susan Slager⁴², Ana Osorio⁴³, Javier Benitez⁴⁴, Mercedes Duran⁴⁵, Jeffrey N Weitzel⁴⁶, Isaac Tafur⁴⁷, Mary Hander⁴⁸, Paolo Peterlongo⁴⁹, Siranoush Manoukian⁵⁰, Bernard Peissel⁵⁰, Gaia Roversi⁵⁰, Giulietta Scuvera⁵⁰, Bernardo Bonanni⁵¹, Paolo Mariani⁵², Sara Volorio⁵², Riccardo Dolcetti⁵³, Liliana Varesco⁵⁴, Laura Papi⁵⁵, Maria Grazia Tibiletti⁵⁶, Giuseppe Giannini⁵⁷, Florentia Fostira⁵⁸, Irene Konstantopoulou⁵⁸, Judy Garber⁵⁹, Ute Hamann⁶⁰, Alan Donaldson⁶¹, Carole Brewer⁶², Claire Foo⁶³, D Gareth Evans⁶⁴, Debra Frost¹, Diana Eccles⁶⁵, EMBRACE Study¹, Fiona Douglas⁶⁶, Angela Brady⁶⁷, Jackie Cook⁶⁸, Marc Tischkowitz⁶⁹, Julian Adlard⁷⁰, Julian Barwell⁷¹, Kai-ren Ong⁷², Lisa Walker⁷³, Louise Izatt⁷⁴, Lucy E Side⁷⁵, M John Kennedy⁷⁶, Mark T Rogers⁷⁷, Mary E Porteous⁷⁸, Patrick J Morrison⁷⁹, Radka Platte¹, Ros Eeles⁸⁰, Rosemarie Davidson⁸¹, Shirley Hodgson⁸², Steve Ellis¹, Andrew K Godwin⁸³, Kerstin Rhiem^{10,11,14}, Alfons Meindl⁸⁴, Nina Ditsch⁸⁵, Norbert Arnold⁸⁶, Hansjoerg Plendl⁸⁷, Dieter Niederacher⁸⁸, Christian Sutter⁸⁹, Doris Steinemann⁹⁰, Nadja Bogdanova-Markov⁹¹, Karin Kast⁹², Raymonda Varon-Mateeva⁹³, Shan Wang-Gohrke⁹⁴, Andrea Gehrig⁹⁵, Birgid Markiefka¹¹, Bruno Buecher⁹⁶, Cédric Lefol⁹⁶, Dominique Stoppa-Lyonnet^{96,97,98}, Etienne Rouleau⁹⁹, Fabienne Prieur¹⁰⁰, Francesca Damiola¹⁰¹, GEMO Study Collaborators¹⁰², Laure Barjhoux¹⁰¹, Laurence Faivre^{103,104}, Michel Longy¹⁰⁵, Nicolas Sevenet¹⁰⁵, Olga M Sinilnikova^{101,106}, Sylvie Mazoyer¹⁰¹, Valérie Bonadona^{107,108}, Virginie Caux-Moncoutier⁹⁶, Claudine Isaacs¹⁰⁹, Tom Van Maerken¹¹⁰, Kathleen Claes¹¹⁰, Marion Piedmonte¹¹¹, Lesley Andrews¹¹², John Hays¹¹³, Gustavo C Rodriguez¹¹⁴, Trinidad Caldes¹¹⁵, Miguel de la Hoya¹¹⁵, Sofia Khan¹⁵, Frans BL Hogervorst¹¹⁶, Cora M Aalfs¹¹⁷, JL de Lange¹¹⁸, Hanne EJ Meijers-Heijboer¹¹⁹, Annemarie H van der Hout¹²⁰, Juul T Wijnen¹²¹, KEP van Roozendaal¹²², Arjen R Mensenkamp¹²³, Ans MW van den Ouweland¹²⁴, Carolien HM van Deurzen¹²⁵, Rob B van der Luijt¹²⁶, HEBON¹²⁷, Edith Olah¹²⁸, Orland Diez¹²⁹, Conxi Lazaro¹³⁰, Ignacio Blanco¹³¹, Alex Teulé¹³¹, Mireia Menendez¹³⁰, Anna Jakubowska¹³², Jan Lubinski¹³², Cezary Cybulski¹³², Jacek Gronwald¹³², Katarzyna Jaworska-Bieniek¹³², Katarzyna Durda¹³², Adalgeir Arason¹³³, Christine Maugard¹³⁴, Penny Soucy¹³⁵, Marco Montagna¹³⁶, Simona Agata¹³⁶, Manuel R Teixeira¹³⁷, KConFab Investigators¹³⁸, Curtis Olswold⁴², Noralane Lindor¹³⁹, Vernon S Pankratz⁴², Emily Hallberg⁴², Xianshu Wang¹⁴⁰, Csilla I Szabo¹⁴¹, Joseph Vijai³, Lauren Jacobs¹⁴², Marina Corines¹⁴², Anne Lincoln¹⁴², Andreas Berger¹⁴³, Anneliese Fink-Retter¹⁴³,

* Correspondence: kbk21@medschl.cam.ac.uk

¹Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

Full list of author information is available at the end of the article

Christian F Singer¹⁴³, Christine Rappaport¹⁴³, Daphne Gschwantler Kaulich¹⁴³, Georg Pfeiler¹⁴³, Muy-Kheng Tea¹⁴³, Catherine M Phelan¹⁴⁴, Phuong L Mai¹⁴⁵, Mark H Greene¹⁴⁵, Gad Rennert¹⁴⁶, Evgeny N Imyanitov¹⁴⁷, Gord Glendon¹⁴⁸, Amanda Ewart Toland¹⁴⁹, Anders Bojesen¹⁵⁰, Inge Sokilde Pedersen¹⁵¹, Uffe Birk Jensen¹⁵², Maria A Caligo¹⁵³, Eitan Friedman¹⁵⁴, Raanan Berger¹⁵⁴, Yael Laitman¹⁵⁴, Johanna Rantala¹⁵⁵, Brita Arver¹⁵⁶, Niklas Loman¹⁵⁷, Ake Borg¹⁵⁸, Hans Ehrencrona^{161,162}, Olufunmilayo I Olopade¹⁶³, Jacques Simard¹³⁵, Douglas F Easton¹, Georgia Chenevix-Trench⁸, Kenneth Offit³, Fergus J Couch^{41,42}, Antonis C Antoniou¹, on behalf of CIMBA¹

Abstract

Introduction: More than 70 common alleles are known to be involved in breast cancer (BC) susceptibility, and several exhibit significant heterogeneity in their associations with different BC subtypes. Although there are differences in the association patterns between *BRCA1* and *BRCA2* mutation carriers and the general population for several loci, no study has comprehensively evaluated the associations of all known BC susceptibility alleles with risk of BC subtypes in *BRCA1* and *BRCA2* carriers.

Methods: We used data from 15,252 *BRCA1* and 8,211 *BRCA2* carriers to analyze the associations between approximately 200,000 genetic variants on the iCOGS array and risk of BC subtypes defined by estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and triple-negative- (TN) status; morphologic subtypes; histological grade; and nodal involvement.

Results: The estimated BC hazard ratios (HRs) for the 74 known BC alleles in *BRCA1* carriers exhibited moderate correlations with the corresponding odds ratios from the general population. However, their associations with ER-positive BC in *BRCA1* carriers were more consistent with the ER-positive associations in the general population (intraclass correlation (ICC) = 0.61, 95% confidence interval (CI): 0.45 to 0.74), and the same was true when considering ER-negative associations in both groups (ICC = 0.59, 95% CI: 0.42 to 0.72). Similarly, there was strong correlation between the ER-positive associations for *BRCA1* and *BRCA2* carriers (ICC = 0.67, 95% CI: 0.52 to 0.78), whereas ER-positive associations in any one of the groups were generally inconsistent with ER-negative associations in any of the others. After stratifying by ER status in mutation carriers, additional significant associations were observed. Several previously unreported variants exhibited associations at $P < 10^{-6}$ in the analyses by PR status, HER2 status, TN phenotype, morphologic subtypes, histological grade and nodal involvement.

Conclusions: Differences in associations of common BC susceptibility alleles between *BRCA1* and *BRCA2* carriers and the general population are explained to a large extent by differences in the prevalence of ER-positive and ER-negative tumors. Estimates of the risks associated with these variants based on population-based studies are likely to be applicable to mutation carriers after taking ER status into account, which has implications for risk prediction.

Introduction

Women who carry pathogenic mutations in *BRCA1* or *BRCA2* have markedly increased risks of developing breast cancer. The distributions of breast cancer tumor characteristics differ between *BRCA1* mutation carriers, *BRCA2* mutation carriers and those arising in the general population. The majority of breast tumors arising in *BRCA1* carriers show low or absent expression of estrogen receptor (ER) [1-3], whereas the majority of *BRCA2*-associated tumors are ER-positive [1,4,5].

Many common breast cancer susceptibility alleles identified through population-based genome-wide association studies (GWASs) have also been associated with breast cancer risk in *BRCA1* and *BRCA2* carriers [6,7]. Several of these variants are specifically associated with the ER status of the breast cancer in the general population [8,9]. Among the single-nucleotide polymorphisms (SNPs) that have been evaluated in mutation carriers so far, the

variants found to be associated with breast cancer risk for *BRCA1* carriers largely overlap with loci for which stronger associations with ER-negative breast cancer have been reported in the general population [8-12]. An important question for risk modelling and prevention studies is whether the effects of common variants on breast cancer risk in mutation carriers are mediated through a generic influence on the development of particular hormone receptor subtypes of breast cancer or through epistatic interaction with the *BRCA1/2* mutation itself.

Previous studies by the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) described the impact of 29 breast cancer susceptibility variants from non-hereditary breast cancer studies on ER-positive and ER-negative breast cancer risk in *BRCA1* and *BRCA2* carriers [6,7,13-15]. These analyses demonstrated that, despite the lack of an association between some susceptibility variants and overall breast cancer risk for *BRCA1*

or *BRCA2* carriers, residual associations exist with specific disease subtypes. In addition, the ER-specific associations in *BRCA1* and *BRCA2* carriers were mainly in the same direction and of a magnitude similar to the associations observed with breast cancer stratified by ER expression status in the general population. However, these studies were conducted on smaller numbers of mutation carriers than currently available and evaluated only a subset of the currently known breast cancer susceptibility alleles for their associations with ER-specific subtypes in carriers. Recently, 45 additional SNPs have been found to be associated with breast cancer risk in the general population [8-10,16]. Eighteen of these SNPs showed evidence of association with ER-positive breast cancer, but not with ER-negative breast cancer, and four loci (1q32.1 *LGR6*, 2p24.1, 16q12 and 20q11) were associated only with ER-negative breast cancer in the general population. These 45 newly discovered loci have not yet been evaluated for their associations with breast cancer risk for mutation carriers.

In the present study, we assessed the disease subtype-specific associations of all 74 previously reported breast cancer susceptibility variants in 15,252 *BRCA1* and 8,211 *BRCA2* carriers. We evaluated whether differences in associations of known breast cancer susceptibility variants between *BRCA1* carriers, *BRCA2* carriers and the general population are mediated by tumor ER status in mutation carriers. We also analyzed the associations of about 200,000 variants on the iCOGS genotyping array with subtype-specific breast cancer risk in carriers in an attempt to uncover previously unreported subtype-specific associations in women with *BRCA1* and *BRCA2* mutations. In addition to ER and progesterone receptor (PR) status, we report, for the first time to our knowledge, associations by HER2 status and with triple-negative disease (TN, referring to ER-, PR- and human epidermal growth factor receptor 2 (HER2)-negative), and we also describe associations with clinical features such as “ductal, no specified subtype” (hereafter referred to as *ductal*) and lobular morphologic subtypes, nodal status and histological grade.

Methods

Study subjects

Data were obtained from 47 studies in 27 different countries in CIMBA [17]. Eligible study subjects were women who carry pathogenic mutations in *BRCA1* or *BRCA2*. The majority were recruited through cancer genetics clinics and enrolled into national or regional studies. Written informed consent was obtained from all subjects. Each of the host institutions recruited under ethically approved protocols. A list of the local institutional review boards that provided ethical approval for this study is given in Additional file 1: Table S1. Eligibility

was restricted to mutation carriers who were 18 years of age or older at recruitment. Data collected included year of birth, age at cancer diagnosis, personal history of bilateral prophylactic mastectomy and/or bilateral salpingo-oophorectomy, mutation description, tumor pathology and ethnicity.

Tumor pathology data

Breast tumor pathology data were gathered from a range of sources, specifically patient pathology reports, pathology review data, tumor registry records and tissue microarray results. These included information on ER, PR and HER2 status; morphologic subtype; lymph node involvement; and histological grade. For ER, PR and HER2, status was classified as negative or positive, with supplementary immunohistochemistry scoring or biochemical data and methodology provided when available. The vast majority of centers employed a cutoff of either $\geq 10\%$ or $\geq 1\%$ of tumor nuclei staining positive to define ER and PR positivity. Additional file 1: Table S2 lists the subtype definitions used by each study, which were not centrally reclassified, owing to the low proportion of records with supporting staining data. Similarly, HER2 status was determined using immunohistochemistry to detect strong complete membrane staining (with a score of 3+ considered positive) and/or *in situ* hybridization to detect HER2 gene amplification. To ensure consistency across studies, when information on the cells stained was available, we used the same cutoff to define ER-, PR- and HER2-positive tumors. The cutoffs used for the small number of cases where composite scoring methods based on the proportion and intensity of staining were available (Allred score, immunoreactive Remmele score) are given in Additional file 1: Table S2. Consistency checks were performed to validate receptor data against supplementary scoring information, if provided. Each cancer was assigned to a morphologic subgroup (ductal, lobular, medullary, other), which we confirmed using the World Health Organization International Classification of Diseases for Oncology (ICD-O) code for the classification of tumor type when sufficient information was provided [18]. Lymph node status, along with the number of nodes showing metastatic carcinoma, was provided when available. Histologic grade was assigned as grade 1, 2 or 3 by local pathologists who used a modified Scarff-Bloom-Richardson malignancy grading system.

Genotyping and quality control

Genotyping was carried out using the iCOGS custom array. The array development and details of the genotyping and quality control for the CIMBA samples are described in detail elsewhere [6,7]. Briefly, genotyping for *BRCA2* carriers was conducted at McGill University and Génome Québec Innovation Centre (Canada) and for

BRCA1 carriers at the Mayo Clinic (USA). SNPs were excluded if they were located on the Y chromosome, if they were monomorphic, if they deviated significantly from Hardy-Weinberg equilibrium ($P < 10^{-7}$) or if they had call rates $< 95\%$. Samples were excluded if they had a call rate $< 95\%$, if they were of non-European ancestry or if they demonstrated extreme heterozygosity. After quality control, we had 200,720 SNPs available for analysis in 15,252 *BRCA1* samples and 200,908 SNPs available for analysis in 8,211 *BRCA2* samples.

Statistical methods

We evaluated the associations of each genotype with risks of developing breast cancer or breast cancer subtypes defined by the tumor characteristics or morphology. The analyses were carried out within a survival analysis framework. Individuals were censored at the first of the following events: breast cancer diagnosis, ovarian cancer diagnosis, bilateral mastectomy or age at last follow-up. In order to account for non-random ascertainment of mutation carriers with respect to their disease phenotype, we used a retrospective likelihood approach that models the probability of observing the genotypes conditional on the disease phenotype [19,20]. It was assumed that the cancer incidence depends on the underlying SNP genotype through a Cox proportional hazards model:

$$\lambda_i(t_i) = \lambda_0(t_i) \exp(\beta z_i),$$

where $\lambda_0(t_i)$ is the baseline incidence and β is the logarithm of the per-allele hazard ratio (HR, under a multiplicative model). The association with overall breast cancer risk was evaluated by testing the hypothesis that $\beta = 0$ [20].

We evaluated the associations with the groups of each subtype class (for example, ER-positive and ER-negative), using an extension of the retrospective likelihood approach to model the simultaneous effect of each SNP on more than one tumor subtype [15]. Briefly, this involves modeling the conditional likelihood of the observed SNP genotypes and tumor subtypes, given the disease phenotypes. Within this framework, it is possible to estimate simultaneously the HRs for each tumor subtype and test for heterogeneity in the associations [15]. To maximize the available information, genotyped mutation carriers that were missing information on tumor characteristics were included in the analysis, and their disease subtype was assumed to be missing at random. In order to account for non-independence among relatives, a robust variance estimation approach was used [20]. Further details of the methods for evaluating the associations with overall breast cancer [20] and tumor subtypes have been described elsewhere [15]. We carried out association analyses by subtype for the following breast cancer characteristics: ER-positive

and ER-negative, PR-positive and PR-negative, HER2-positive and HER2-negative, TN breast cancer (that is, negative for ER, PR and HER2) and non-TN (that is, tumor positive for at least one of the three receptors), ductal morphologic subtype, lobular morphologic subtype, nodal involvement (no involved lymph nodes and at least one involved lymph node) and histological grade (high grade (grade 3) and non-high grade (grades 1 and 2)). Only samples with complete information on ER, PR and HER2 expression were included in the analysis for TN as well as non-TN breast cancer. The SNP associations by tumor morphologic subtype were evaluated by comparing ductal tumors to all others and, in a separate analysis, lobular tumors to all others. We are not reporting association analyses for risk of medullary morphologic subtype, owing to sparse data as well as the difficulties in diagnosing medullary breast tumors reliably [21,22]. All analyses were stratified by country of residence. The United States and Canada strata were further subdivided by reported Ashkenazi Jewish ancestry. For subtypes with small groups, strata of geographically close countries were combined to provide sufficiently large groups for estimation. All analyses used calendar year- and cohort-specific cancer incidences for *BRCA1* and *BRCA2*. SNPs with minor allele frequencies $< 3\%$ were excluded. The retrospective likelihood was modeled using custom-written functions implemented in the pedigree analysis software MENDEL [23].

When evaluating whether the known breast cancer susceptibility loci identified through population based studies also modify breast cancer risk in mutation carriers, a significance threshold of $P < 0.05$ was used because of the strong prior evidence of association for these loci with disease risk. For the association analyses of all the approximately 200,000 variants on the iCOGS array with the breast cancer subtypes in mutation carriers, only associations with $P < 5 \times 10^{-8}$ were considered significant. The discussion of findings and the tables were extended to associations at $P < 10^{-6}$.

For variants associated with ER-positive or ER-negative breast cancer with $P < 0.01$, we evaluated whether the associations may have been affected by a possible survival bias due to inclusion of prevalent breast cancer cases in the analysis. For the sensitivity analysis, the association analysis by ER status was repeated after excluding mutation carriers diagnosed with breast cancer ≥ 5 years prior to study recruitment.

We evaluated the consistency between the breast cancer association estimates of previously reported breast cancer susceptibility variants in the general population (using published data) and the association estimates in *BRCA1* and *BRCA2* carriers using the intraclass correlation (ICC). We estimated ICC as outlined by Shrout and Fleiss [24] based on a one-way random-effects model and tested for agreement in absolute values of log HR. The

same approach was used to evaluate the agreement between associations with ER-positive and/or -negative breast cancer in the general population and associations with ER-positive and/or -negative breast cancer in *BRCA1* and in *BRCA2* carriers. Furthermore, we carried out the same comparisons between associations for *BRCA1* and associations for *BRCA2* carriers.

Results

Subtype patterns

The analyses included data from 15,252 *BRCA1* carriers and 8,211 *BRCA2* carriers. Among the breast cancer-affected *BRCA1* carriers, we had data on at least one disease characteristic of interest for 4,619 (59%) of the 7,797 affected women (Table 1). Data were available on tumor characteristics for 2,570 (59%) of the 4,330 affected *BRCA2* carriers. Of the individuals with pathology information, 74% of the *BRCA1* carriers and 75% of the *BRCA2* carriers had data on ER status.

Single-nucleotide polymorphism associations

After quality control, genotype data were available for analysis for 200,720 SNPs for *BRCA1* carriers and for

200,908 SNPs for *BRCA2* carriers. After adjusting for sample size and excluding SNPs chosen for inclusion on the genotyping array based on reported associations in subsets of the current sample, the inflation coefficient λ_{1000} values were 1.01 for ER-positive disease in *BRCA1* carriers, 1.02 for ER-negative in *BRCA1*, 1.01 for ER-positive in *BRCA2* and 1.02 for ER-negative in *BRCA2* carriers (Additional file 1: Figure S1 and Figure S2). Similar patterns were observed for other tumor characteristics (results not shown). After excluding variants located at known breast cancer susceptibility loci, there was no evidence for an excess in associations by ER status beyond the number expected.

Associations of previously reported breast cancer susceptibility loci

Associations with overall breast cancer and by tumor estrogen receptor status

First, we considered the associations with risk for overall breast cancer and for tumor subtypes for the 74 breast cancer susceptibility variants that have been reported up to April 2013. In light of the strong prior evidence of association, we considered associations at $P < 0.05$ as

Table 1 Breast tumor characteristics of 7,797 affected *BRCA1* mutation carriers and 4,330 affected *BRCA2* mutation carriers^a

	<i>BRCA1</i> mutation carriers			<i>BRCA2</i> mutation carriers		
	Yes, <i>n</i> (%)	No, <i>n</i> (%)	Unknown status	Yes, <i>n</i> (%)	No, <i>n</i> (%)	Unknown status
Predictive markers						
ER-positive	819 (24)	2,639 (76)	4,339	1,490 (77)	434 (23)	2,406
PR-positive	662 (21)	2,485 (79)	4,650	1,099 (65)	591 (35)	2,640
HER2-positive	182 (9)	1,816 (91)	5,799	121 (13)	847 (87)	3,362
Non-TN	580 (31)	1,310 (69)	5,907	760 (85)	136 (15)	3,434
Morphology			3,789			2,087
Ductal	3,159 (82)			1,770 (79)		
Lobular	89 (2)			188 (8)		
Medullary	290 (6)			39 (2)		
Other	470 (10)			246 (11)		
Grade			4,645			3,840
Grade 1	81 (3)			113 (7)		
Grade 2	574 (18)			700 (42)		
Grade 3	2,497 (79)			839 (51)		
Nodal involvement	1,103 (33)	2,274 (67)	4,420	804 (43)	1,068 (57)	2,458
Stage			5,991			3,382
Stage 0 ^b	65 (4)			121 (13)		
Stage 1	825 (46)			327 (35)		
Stage 2	772 (43)			390 (41)		
Stage 3	127 (7)			96 (10)		
Stage 4	17 (1)			14 (1)		

^aER, Estrogen receptor positive; HER2, Human epidermal growth factor receptor 2; PR, Progesterone receptor; TN, Triple-negative. ^bCarcinoma *in situ*.

evidence that a previously reported breast cancer susceptibility allele also modifies overall or ER-specific breast cancer risk in mutation carriers. The associations with overall breast cancer risk and risk of breast cancer subtypes for all 74 variants are given in Table 2 and Additional file 1: Tables S4 to S10. Of the breast cancer susceptibility loci that had not previously been evaluated for an association in mutation carriers, SNPs at 5q33.3, 8q24.21, 11q24.3, 12q22, 16q12.1, 22q13.1 were associated with overall breast cancer risk for *BRCA1* carriers, and SNPs at 6p23, 11q24.3 and 16q12.1 were associated with breast cancer risk for *BRCA2* carriers at $P < 0.05$ (Table 2). Overall, 15 breast cancer susceptibility variants were associated with ER-negative breast cancer in *BRCA1* carriers and 8 variants in *BRCA2* carriers at $P < 0.05$ (Table 2). Ten significant associations with ER-positive breast cancer in *BRCA1* carriers and fourteen in *BRCA2* carriers were found. The strongest association with ER-positive breast cancer was observed for rs2981579 in *FGFR2* at 10q26.12 for both *BRCA1* and *BRCA2* carriers. SNP rs10069690 in *TERT* at 5p15.33 displayed the strongest association with ER-negative breast cancer for *BRCA1* carriers and rs9348512 at 6p24.3 for *BRCA2* carriers. We found significant differences in the associations by ER status for rs3803662 in *TOX3* at 16q12.1 ($P = 2 \times 10^{-4}$) and rs13387042 at 2q35 ($P = 0.002$) for *BRCA1* carriers, which were not previously seen. Both SNPs showed evidence of association with ER-positive breast cancer only. Similarly, six of the loci that did not show evidence of association with overall breast cancer were associated with ER-positive and two with ER-negative breast cancer in *BRCA1* carriers. This included two of the loci not previously evaluated in mutation carriers: 3q26.1 and 6p25.3. In *BRCA2* carriers, four of the variants lacking evidence of association with overall breast cancer were associated with ER-negative and three with ER-positive breast cancer. This included four loci not previously evaluated in mutation carriers: 2q24, 14q13.3, 19q13.31 and 22q12.2. Of the breast cancer susceptibility loci that had not yet been evaluated for an association with breast cancer in mutation carriers, rs1011970 at *CDKN2A/B* and rs1292011 at 12q24.21 had significantly different associations with ER-positive and ER-negative cancer for *BRCA1* carriers ($P_{\text{het}} = 0.009$ and $P_{\text{het}} = 0.004$, respectively, for the difference between ER-positive and ER-negative). SNP rs2236007 at 14q13.3 displayed differences by ER status for *BRCA2* carriers ($P_{\text{het}} = 0.008$). These three SNPs had associations in different directions for ER-positive and ER-negative tumors.

When association analyses for ER-positive and -negative disease were repeated after excluding prevalent breast cancer cases (Additional file 1: Table S3), the HR estimates were consistent with the estimates from the complete sample but were associated with larger confidence

intervals. Therefore, it is unlikely that our results are influenced by survival bias.

Associations with other subtypes and clinical features

The pattern of associations of previously reported breast cancer susceptibility variants by PR and TN status were very similar to that by ER status (Additional file 1: Tables S4 and S6), but fewer associations were observed at $P < 0.01$. SNP rs720475 at 7q35 was the only variant that was associated with HER2-positive disease (HR = 1.45 and $P = 0.003$ for HER2-positive, $P_{\text{het}} = 9 \times 10^{-4}$ in *BRCA2* carriers) (Additional file 1: Table S5).

For *BRCA1* carriers, there were significant differences ($P_{\text{het}} < 0.01$) in the HR for high grade (grade 3) and grades 1 and 2 breast cancer for SNPs at 10q26.12 (*FGFR2*) and at 12q24.21 (Additional file 1: Table S9). SNP rs3803662 in *TOX3* at 16q12.1 was associated exclusively with node-positive breast cancer ($P = 2 \times 10^{-4}$, $P_{\text{het}} = 0.005$) (Additional file 1: Table S10). This was also the only variant associated with lobular cancer, as shown in Additional file 1: Table S8 ($P = 8 \times 10^{-6}$ for *BRCA2* carriers). The HR for lobular cancer was larger than that for non-lobular cancer (lobular HR = 1.57, 95% CI: 1.29 to 1.92; non-lobular HR = 1.20, 95% CI: 1.13 to 1.28 for *BRCA2* carriers; $P_{\text{het}} = 9 \times 10^{-4}$). There was no evidence for differences in associations by histological grade and nodal involvement for *BRCA2* carriers.

Comparison of patterns of associations by breast cancer estrogen receptor status between *BRCA1* and *BRCA2* carriers and the general population

We compared the log HR estimates for the breast cancer association of known breast cancer susceptibility variants for *BRCA1* carriers, *BRCA2* carriers, and for the general population using published data from the Breast Cancer Association Consortium (BCAC) [8]. The resulting ICC coefficients for log HR/OR estimates for all comparisons are shown in Table 3. Log HR estimates for overall breast cancer risk in *BRCA2* carriers were very similar to the log odds ratios (ORs) from the general population (ICC = 0.63, 95% CI: 0.47 to 0.75) (Additional file 1: Figure S3B), whereas there was only moderate correlation between the log HR estimates for *BRCA1* carriers and the log HR estimates from both other groups (ICC: *BRCA1*-BCAC estimates = 0.43, *BRCA1*-*BRCA2* = 0.46) (Additional file 1: Figure S3A,C). When comparing ER-positive specific associations, we found stronger agreement between the log HR/OR estimates than for overall breast cancer. The ICC estimates ranged from 0.61 (95% CI: 0.45 to 0.74) (Figure 1B) for BCAC-*BRCA1* to 0.69 (95% CI: 0.55 to 0.79) (Figure 1C) for BCAC-*BRCA2*. The ER-negative breast cancer log HR estimates in *BRCA1* carriers and the corresponding BCAC estimates were strongly correlated (ICC = 0.59, 95% CI: 0.42 to

Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancer^a

Locus	SNP	Position ^b	Nearby gene	Ref ^c	Eff ^d	K ^e	BRCA1 carriers							
							MAF	Overall HR (95% CI)	P-value	ER-negative HR (95% CI)	P-value	ER-positive HR (95% CI)	P-value	P _{het} -value ^f
1p36.22	rs616488	10566215	<i>PEX14</i>	A	G	No	0.32	0.96 (0.92 to 1.01)	0.10	0.95 (0.90 to 1.00)	0.07	1.00 (0.90 to 1.10)	0.92	0.47
1p13.2	rs12022378	114448389	<i>SYT6</i>	G	A	No	0.16	1.03 (0.98 to 1.09)	0.25	1.03 (0.97 to 1.10)	0.31	1.03 (0.90 to 1.17)	0.68	0.94
1p11.2	rs11249433	121280613	<i>FCGR1B</i>	A	G	Yes	0.41	0.99 (0.95 to 1.04)	0.78	0.99 (0.94 to 1.03)	0.55	1.02 (0.93 to 1.13)	0.63	0.50
1q32.1a	rs6678914	202187176	<i>LGR6</i>	G	A	No	0.4	0.98 (0.94 to 1.02)	0.39	0.96 (0.91 to 1.01)	0.08	1.06 (0.97 to 1.17)	0.21	0.07
1q32.1b	rs4245739	204518842	<i>MDM4</i>	A	C	Yes	0.28	1.10 (1.05 to 1.15)	4.6 × 10⁻⁵	1.12 (1.07 to 1.19)	1.4 × 10⁻⁵	1.02 (0.91 to 1.13)	0.76	0.11
2p24.1	rs12710696	19320803	<i>OSR1</i>	G	A	No	0.39	1.01 (0.97 to 1.06)	0.51	1.01 (0.97 to 1.07)	0.57	1.01 (0.92 to 1.12)	0.77	1.00
2q14.2	rs4849887	121245122		G	A	No	0.11	1.02 (0.96 to 1.09)	0.53	1.01 (0.94 to 1.09)	0.78	1.05(0.90 to 1.23)	0.49	0.64
2q31.1	rs2016394	172972971	<i>DLX2</i>	G	A	No	0.47	1.01 (0.97 to 1.06)	0.54	1.03 (0.98 to 1.08)	0.23	0.96 (0.87 to 1.06)	0.39	0.21
2q31.1	rs1550623	174212894	<i>CDCA7</i>	A	G	No	0.15	1.01 (0.95 to 1.07)	0.72	1.02 (0.95 to 1.09)	0.54	0.97 (0.85 to 1.12)	0.72	0.57
2q35	rs13387042	217905832	<i>TNP1</i>	A	G	Yes	0.47	0.98 (0.94 to 1.02)	0.41	1.02 (0.97 to 1.07)	0.37	0.86 (0.78 to 0.95)	1.9 × 10⁻³	2.3 × 10⁻³
2q35	rs16857609	218296508	<i>DIRC3</i>	G	A	No	0.26	1.04 (1.00 to 1.09)	0.06	1.03 (0.98 to 1.09)	0.23	1.08 (0.97 to 1.21)	0.14	0.47
3p26.1	rs6762644	4742276	<i>ITPR1</i>	A	G	No	0.36	1.04 (0.99 to 1.08)	0.09	1.00 (0.95 to 1.05)	0.92	1.16 (1.05 to 1.28)	2.9 × 10⁻³	0.01
3p24.1	rs4973768	27416013	<i>SLC4A7</i>	G	A	Yes	0.49	1.01 (0.97 to 1.06)	0.47	0.99 (0.95 to 1.04)	0.81	1.09 (0.99 to 1.19)	0.07	0.10
3p24.1	rs12493607	30682939	<i>TGFBR2</i>	C	G	No	0.35	0.99 (0.95 to 1.04)	0.73	0.99 (0.94 to 1.04)	0.63	1.01 (0.92 to 1.11)	0.85	0.70
4q24	rs9790517	106084778	<i>TET2</i>	G	A	No	0.23	0.98 (0.94 to 1.03)	0.51	0.97 (0.92 to 1.03)	0.30	1.03 (0.92 to 1.15)	0.61	0.37
4q34.1	rs6828523	175846426	<i>EBF1</i>	C	A	No	0.11	1.03 (0.96 to 1.1)	0.41	1.03 (0.95 to 1.11)	0.47	1.02 (0.88 to 1.19)	0.78	0.94
5p15.33	rs10069690	1279790	<i>TERT</i>	G	A	Yes	0.28	1.21 (1.15 to 1.26)	1.1 × 10⁻¹⁵	1.24 (1.18 to 1.31)	2.7 × 10⁻¹⁵	1.09 (0.98 to 1.22)	0.09	0.04
5p15.33	rs7725218	1282414	<i>TERT</i>	G	A	Yes	0.36	1.08 (1.04 to 1.13)	3.2 × 10⁻⁴	1.09 (1.04 to 1.15)	6.4 × 10⁻⁴	1.05 (0.95 to 1.15)	0.37	0.47
5p15.33	rs2736108	1297488	<i>TERT</i>	G	A	Yes	0.29	0.89 (0.85 to 0.93)	4.2 × 10⁻⁷	0.86 (0.82 to 0.91)	1.1 × 10⁻⁷	0.98 (0.88 to 1.08)	0.68	0.04
5p12	rs10941679	44706498	<i>MRPS30</i>	A	G	Yes	0.25	0.99 (0.94 to 1.04)	0.61	0.99 (0.94 to 1.05)	0.84	0.97 (0.86 to 1.08)	0.54	0.66
5q11.2	rs889312	56031884	<i>MAP3K1</i>	A	C	Yes	0.29	1.01 (0.97 to 1.06)	0.52	0.99 (0.94 to 1.05)	0.82	1.09 (0.98 to 1.21)	0.12	0.15
5q11.3	rs10472076	58184061	<i>RAB3C</i>	A	G	No	0.37	1.00 (0.96 to 1.05)	0.83	0.98 (0.94 to 1.03)	0.52	1.08 (0.98 to 1.18)	0.13	0.11
5q11.3	rs1353747	58337481	<i>PDE4D</i>	A	C	No	0.09	0.98 (0.91 to 1.05)	0.53	0.95 (0.88 to 1.04)	0.28	1.06 (0.90 to 1.24)	0.50	0.29
5q33.3	rs1432679	158244083		A	G	No	0.44	1.05 (1.00 to 1.09)	0.03	1.03 (0.98 to 1.08)	0.25	1.10 (1.01 to 1.21)	0.04	0.21
6p25.3	rs11242675	1318878	<i>FOXQ1</i>	A	G	No	0.35	0.96 (0.92 to 1)	0.06	0.94 (0.90 to 0.99)	0.03	1.01 (0.91 to 1.11)	0.90	0.28
6p24.3	rs9348512	10456706	<i>TFAP2A</i>	C	A	Yes	0.34	1.00 (0.95 to 1.04)	0.87	1.00 (0.95 to 1.05)	0.88	1.00 (0.90 to 1.10)	0.95	1.00
6p23	rs204247	13722523	<i>RANBP9</i>	A	G	No	0.44	1.00 (0.96 to 1.04)	0.98	1.00 (0.95 to 1.04)	0.84	1.01 (0.92 to 1.12)	0.75	0.72
6q14	rs17530068	82193109	<i>FAM46A</i>	A	G	Yes	0.25	1.03 (0.98 to 1.08)	0.23	1.03 (0.97 to 1.09)	0.29	1.03 (0.92 to 1.14)	0.63	0.95
6q25.1	rs3757318	151914113	<i>ESR1</i>	G	A	Yes	0.08	1.20 (1.11 to 1.29)	1.1 × 10⁻⁶	1.24 (1.14 to 1.35)	5.6 × 10⁻⁷	1.06 (0.89 to 1.26)	0.51	0.12
6q25.1	rs2046210	151948366	<i>ESR1</i>	G	A	Yes	0.37	1.16 (1.12 to 1.21)	2.4 × 10⁻¹²	1.20 (1.15 to 1.26)	2.8 × 10⁻¹³	1.04 (0.94 to 1.15)	0.42	0.01

Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancer^a (Continued)

7q35	rs720475	144074929	<i>ARHGEF5</i>	G	A	Yes	0.26	0.98 (0.93 to 1.03)	0.36	0.98 (0.93 to 1.04)	0.54	0.96 (0.86 to 1.08)	0.53	0.79
8p12	rs9693444	29509616	<i>DUSP4</i>	C	A	Yes	0.33	1.01 (0.96 to 1.05)	0.80	1.01 (0.96 to 1.06)	0.69	0.99 (0.90 to 1.09)	0.83	0.72
8q21.11	rs6472903	76230301		A	C	Yes	0.17	1.01 (0.96 to 1.07)	0.74	1.01 (0.95 to 1.08)	0.77	1.01 (0.89 to 1.14)	0.89	0.99
8q21.11	rs2943559	76417937	<i>HNF4G</i>	A	G	Yes	0.08	1.06 (0.98 to 1.14)	0.12	1.07 (0.98 to 1.17)	0.12	1.02 (0.86 to 1.22)	0.78	0.68
8q24.21	rs11780156	129194641	<i>MYC</i>	G	A	No	0.19	0.95 (0.9 to 1)	0.05	0.96 (0.90 to 1.02)	0.15	0.93 (0.82 to 1.05)	0.23	0.70
8q24.21	rs13281615	128355618		A	G	Yes	0.43	1.02 (0.98 to 1.06)	0.44	1.01 (0.96 to 1.06)	0.73	1.04 (0.95 to 1.15)	0.38	0.55
9p21.3	rs1011970	22062134	<i>CDKN2B</i>	C	A	Yes	0.17	1.02 (0.97 to 1.08)	0.47	1.07 (1.00 to 1.14)	0.05	0.87 (0.76 to 0.99)	0.04	9.3 × 10⁻³
9q31.2	rs10759243	110306115	<i>KLF4</i>	C	A	No	0.31	0.98 (0.94 to 1.02)	0.39	0.98 (0.93 to 1.03)	0.49	0.98 (0.88 to 1.08)	0.64	0.93
9q31.2	rs865686	110888478	<i>KLF4</i>	A	C	Yes	0.36	0.99 (0.95 to 1.04)	0.77	1.02 (0.97 to 1.07)	0.52	0.92 (0.83 to 1.02)	0.11	0.10
10p12.31	rs7072776	22032942	<i>MLLT10</i>	G	A	No	0.31	0.99 (0.94 to 1.03)	0.52	0.96 (0.91 to 1.01)	0.11	1.08 (0.98 to 1.20)	0.12	0.04
10p12.31	rs11814448	22315843	<i>DNAJC1</i>	A	C	No	0.02			1.10 (0.94 to 1.29)	0.22	1.25 (0.93 to 1.69)	0.15	0.50
10q21.2	rs10995190	64278682	<i>ZNF365</i>	G	A	Yes	0.15	0.99 (0.93 to 1.05)	0.70	1.02 (0.96 to 1.09)	0.49	0.88 (0.76 to 1.00)	0.06	0.05
10q22.3	rs704010	80841148	<i>ZMIZ1</i>	G	A	Yes	0.37	1.01 (0.97 to 1.06)	0.48	0.99(0.94 to 1.04)	0.61	1.12 (1.01 to 1.23)	0.03	0.03
10q25.2	rs7904519	114773927	<i>TCF7L2</i>	A	G	Yes	0.47	1.09 (1.05 to 1.14)	1.6 × 10⁻⁵	1.09 (1.04 to 1.14)	6.4 × 10⁻⁴	1.12 (1.02 to 1.23)	0.02	0.59
10q26.12	rs2981579	123337335	<i>FGFR2</i>	G	A	Yes	0.42	0.99 (0.95 to 1.04)	0.81	0.92 (0.87 to 0.96)	6.9 × 10⁻⁴	1.29 (1.17 to 1.43)	3.1 × 10⁻⁷	7.5 × 10⁻⁹
10q26.12	rs11199914	123093901	<i>FGFR2</i>	G	A	No	0.33	1.02 (0.98 to 1.07)	0.27	1.04 (0.99 to 1.10)	0.09	0.96 (0.86 to 1.06)	0.43	0.17
11p15.5	rs3817198	1909006	<i>LSP1</i>	A	G	Yes	0.33	1.08 (1.03 to 1.13)	6.5 × 10⁻⁴	1.08 (1.03 to 1.14)	2.9 × 10⁻³	1.07 (0.97 to 1.18)	0.17	0.89
11q13.1	rs3903072	65583066	<i>SNX32</i>	C	A	No	0.47	0.99 (0.95 to 1.03)	0.69	1.00 (0.95 to 1.05)	0.94	0.96 (0.87 to 1.05)	0.39	0.44
11q13.3	rs554219	69331642	<i>CCND1</i>	C	G	Yes	0.12	1.03 (0.97 to 1.09)	0.37	1.00 (0.93 to 1.08)	0.96	1.12 (0.97 to 1.29)	0.12	0.20
11q13.3	c11_pos690 88342	69379161		C	A	Yes	0.06	1.03 (0.95 to 1.13)	0.45	1.00 (0.90 to 1.12)	0.95	1.14 (0.93 to 1.39)	0.20	0.30
11q13.3	rs494406	69344241		G	A	Yes	0.25	1.02 (0.97 to 1.07)	0.46	1.02 (0.97 to 1.08)	0.42	1.00 (0.90 to 1.12)	0.97	0.74
11q24.3	rs11820646	129461171	<i>BARX2</i>	G	A	No	0.39	0.93 (0.89 to 0.97)	5.9 × 10⁻⁴	0.94 (0.90 to 0.99)	0.03	0.88 (0.79 to 0.97)	8.9 × 10⁻³	0.20
12p13.1	rs12422552	14413931	<i>ATF7IP</i>	G	C	No	0.27	1.01 (0.97 to 1.06)	0.63	1.01 (0.96 to 1.07)	0.68	1.01 (0.91 to 1.13)	0.85	0.99
12p11.22	rs10771399	28155080	<i>PTHLH</i>	A	G	Yes	0.10	0.85 (0.80 to 0.91)	1.9 × 10⁻⁶	0.83 (0.77 to 0.9)	1.2 × 10⁻⁵	0.91 (0.78 to 1.06)	0.24	0.36
12q22	rs17356907	96027759	<i>NTN4</i>	A	G	No	0.29	0.95 (0.91 to 1.00)	0.03	0.94 (0.90 to 1.00)	0.03	0.98 (0.88 to 1.09)	0.71	0.56
12q24.21	rs1292011	115836522	<i>TBX3</i>	A	G	Yes	0.41	1.00 (0.96 to 1.05)	0.82	1.04 (0.99 to 1.10)	0.08	0.88 (0.80 to 0.97)	0.01	4.39 × 10⁻³
13q13.1	rs11571833	32972626	<i>BRCA2</i>	T	A	No	0.01	1.02 (0.83 to 1.26)	0.83	1.05 (0.83 to 1.34)	0.66	0.92 (0.53 to 1.59)	0.75	0.66
14q13.3	rs2236007	37132769	<i>PAX9</i>	G	A	No	0.21	0.97 (0.92 to 1.02)	0.19	0.95 (0.90 to 1.01)	0.13	1.01 (0.90 to 1.14)	0.87	0.42
14q24.1	rs2588809	68660428		G	A	No	0.19	0.96 (0.91 to 1.01)	0.09	0.95 (0.89 to 1.01)	0.13	0.97 (0.86 to 1.09)	0.56	0.85
14q24.1	rs999737	69034682	<i>RAD51L1</i>	G	A	Yes	0.21	0.96 (0.91 to 1.01)	0.09	0.98 (0.92 to 1.04)	0.43	0.90 (0.80 to 1.01)	0.07	0.22
14q32.11	rs941764	91841069	<i>CCDC88C</i>	A	G	No	0.34	1.03 (0.98 to 1.07)	0.23	1.02 (0.97 to 1.07)	0.47	1.05 (0.95 to 1.17)	0.34	0.62
16q12.1a	rs3803662	52586341	<i>TOX3</i>	G	A	Yes	0.29	1.06 (1.01 to 1.11)	0.02	1.01 (0.96 to 1.07)	0.65	1.22 (1.10 to 1.35)	1.5 × 10⁻⁴	2.39 × 10⁻³
16q12.1b	rs11075995	53855291	<i>FTO</i>	A	T	No	0.24	1.01 (0.96 to 1.06)	0.61	0.98 (0.93 to 1.04)	0.60	1.11 (0.99 to 1.24)	0.07	0.07

Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancer^a (Continued)

16q12.1b	rs17817449	53813367	<i>FTO</i>	A	C	No	0.41	0.95 (0.91 to 0.99)	0.02	0.94 (0.89 to 0.98)	9.8 × 10⁻³	1.00 (0.91 to 1.10)	0.99	0.26
16q23.2	rs13329835	80650805	<i>CDYL2</i>	A	G	No	0.23	1.04 (0.99 to 1.09)	0.09	1.03 (0.97 to 1.09)	0.29	1.08 (0.97 to 1.21)	0.17	0.48
17q22	rs6504950	53056471	<i>COX11</i>	G	A	Yes	0.27	0.98 (0.94 to 1.03)	0.49	0.99 (0.94 to 1.04)	0.70	0.96 (0.87 to 1.07)	0.49	0.68
18q11.2	rs527616	24337424	<i>AQP4</i>	C	G	No	0.37	0.99 (0.95 to 1.03)	0.61	0.97 (0.93 to 1.02)	0.30	1.04 (0.94 to 1.15)	0.42	0.26
18q11.2	rs1436904	22824665		A	C	No	0.39	0.99 (0.95 to 1.03)	0.68	1.00 (0.95 to 1.05)	0.86	0.98 (0.89 to 1.08)	0.63	0.74
19p13.11	rs8170	17389704	<i>BABAM1</i>	G	A	Yes	0.19	1.19 (1.12 to 1.25)	2.9 × 10⁻¹⁰	1.22 (1.15 to 1.30)	1.7 × 10⁻¹⁰	1.06 (0.95 to 1.20)	0.30	0.05
19p13.11	rs4808801	18571141	<i>ELL</i>	A	G	No	0.32	0.98 (0.94 to 1.02)	0.40	0.99 (0.94 to 1.05)	0.81	0.94 (0.85 to 1.04)	0.23	0.35
19q13.31	rs3760982	44286513	<i>KCNN4</i>	G	A	No	0.46	1.03 (0.99 to 1.08)	0.10	1.03 (0.98 to 1.08)	0.19	1.04 (0.95 to 1.14)	0.41	0.90
21q21.1	rs2823093	16520832	<i>NRIP1</i>	G	A	Yes	0.27	0.95 (0.91 to 1)	0.04	0.96 (0.91 to 1.02)	0.17	0.92 (0.82 to 1.02)	0.11	0.44
22q12.2	rs132390	29621477	<i>EMID1</i>	A	G	No	0.03	0.98 (0.87 to 1.1)	0.75	0.93 (0.81 to 1.07)	0.30	1.16 (0.91 to 1.46)	0.23	0.13
22q13.1	rs6001930	40876234	<i>SGSM3</i>	A	G	No	0.11	1.07 (1.00 to 1.14)	0.03	1.06 (0.98 to 1.15)	0.14	1.11 (0.96 to 1.30)	0.17	0.60

Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancer^a

Locus	SNP	Position ^b	Nearby gene	Ref ^c	Eff ^d	K ^e	BRCA2 carriers							
							MAF	Overall		ER-negative		ER-positive		P _{net} -value ^f
								HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	
1p36.22	rs616488	10566215	<i>PEX14</i>	A	G	No	0.33	0.98 (0.92 to 1.04)	0.52	1.01 (0.88 to 1.16)	0.94	0.97 (0.9 to 1.05)	0.46	0.69
1p13.2	rs12022378	114448389	<i>SYT6</i>	G	A	No	0.17	1.03 (0.95 to 1.12)	0.42	1.16 (0.97 to 1.37)	0.10	1.00 (0.91 to 1.1)	1.00	0.15
1p11.2	rs11249433	121280613	<i>FCGR1B</i>	A	G	Yes	0.41	1.05 (0.99 to 1.12)	0.09	1.04 (0.91 to 1.19)	0.57	1.06 (0.99 to 1.13)	0.12	0.84
1q32.1a	rs6678914	202187176	<i>LGR6</i>	G	A	No	0.41	1.04 (0.98 to 1.10)	0.19	0.94 (0.82 to 1.08)	0.39	1.07 (1.00 to 1.15)	0.05	0.11
1q32.1b	rs4245739	204518842	<i>MDM4</i>	A	C	Yes	0.28	0.97 (0.91 to 1.04)	0.38	1.09 (0.95 to 1.26)	0.21	0.94 (0.87 to 1.01)	0.10	0.07
2p24.1	rs12710696	19320803	<i>OSR1</i>	G	A	No	0.38	1.00 (0.94 to 1.06)	0.99	1.14 (1.00 to 1.30)	0.05	0.96 (0.9 to 1.03)	0.28	0.02
2q14.2	rs4849887	121245122		G	A	No	0.11	0.98 (0.89 to 1.08)	0.72	1.08 (0.87 to 1.33)	0.49	0.96 (0.85 to 1.07)	0.43	0.34
2q31.1	rs2016394	172972971	<i>DLX2</i>	G	A	No	0.46	0.99 (0.93 to 1.05)	0.74	1.07 (0.94 to 1.22)	0.32	0.97 (0.9 to 1.04)	0.36	0.21
2q31.1	rs1550623	174212894	<i>CDCA7</i>	A	G	No	0.15	0.97 (0.89 to 1.06)	0.49	1.03 (0.87 to 1.23)	0.70	0.95 (0.87 to 1.05)	0.31	0.41
2q35	rs13387042	217905832	<i>TNP1</i>	A	G	Yes	0.48	0.99 (0.93 to 1.05)	0.68	0.98 (0.87 to 1.12)	0.82	0.99 (0.93 to 1.06)	0.74	0.96
2q35	rs16857609	218296508	<i>DIRC3</i>	G	A	No	0.27	0.96 (0.90 to 1.03)	0.26	0.87 (0.74 to 1.01)	0.08	0.99 (0.92 to 1.07)	0.82	0.14
3p26.1	rs6762644	4742276	<i>ITPR1</i>	A	G	No	0.37	0.98 (0.93 to 1.05)	0.61	1.08 (0.94 to 1.24)	0.27	0.96 (0.89 to 1.03)	0.24	0.13
3p24.1	rs4973768	27416013	<i>SLC4A7</i>	G	A	Yes	0.5	1.08 (1.02 to 1.15)	7.8 × 10⁻³	1.05 (0.92 to 1.20)	0.46	1.10 (1.02 to 1.18)	0.01	0.58
3p24.1	rs12493607	30682939	<i>TGFB2</i>	C	G	No	0.34	0.98 (0.92 to 1.04)	0.54	1.07 (0.93 to 1.22)	0.35	0.96 (0.89 to 1.03)	0.23	0.17
4q24	rs9790517	106084778	<i>TET2</i>	G	A	No	0.22	0.97 (0.91 to 1.05)	0.48	0.91 (0.77 to 1.07)	0.25	0.99 (0.91 to 1.08)	0.88	0.35
4q34.1	rs6828523	175846426	<i>EBF1</i>	C	A	No	0.1	0.98 (0.89 to 1.08)	0.72	1.05 (0.85 to 1.30)	0.64	0.96 (0.86 to 1.08)	0.51	0.49
5p15.33	rs10069690	1279790	<i>TERT</i>	G	A	Yes	0.27	1.11 (1.04 to 1.19)	1.6 × 10⁻³	1.25 (1.08 to 1.44)	3.2 × 10⁻³	1.08 (1.00 to 1.17)	0.06	0.09
5p15.33	rs7725218	1282414	<i>TERT</i>	G	A	Yes	0.36	1.06 (0.99 to 1.12)	0.08	1.07 (0.93 to 1.23)	0.35	1.05 (0.98 to 1.13)	0.17	0.85
5p15.33	rs2736108	1297488	<i>TERT</i>	G	A	Yes	0.3	0.93(0.88 to 1.00)	0.04	0.91 (0.78 to 1.05)	0.20	0.94 (0.87 to 1.02)	0.13	0.67
5p12	rs10941679	44706498	<i>MRPS30</i>	A	G	Yes	0.24	1.07 (1.00 to 1.15)	0.03	1.09 (0.94 to 1.27)	0.24	1.07 (0.99 to 1.15)	0.09	0.78
5q11.2	rs889312	56031884	<i>MAP3K1</i>	A	C	Yes	0.3	1.04 (0.98 to 1.11)	0.21	0.99 (0.86 to 1.14)	0.90	1.06 (0.98 to 1.14)	0.14	0.44
5q11.3	rs10472076	58184061	<i>RAB3C</i>	A	G	No	0.38	0.99 (0.93 to 1.05)	0.78	1.02 (0.89 to 1.17)	0.78	0.98 (0.92 to 1.05)	0.64	0.66
5q11.3	rs1353747	58337481	<i>PDE4D</i>	A	C	No	0.09	0.95 (0.86 to 1.05)	0.35	1.02 (0.81 to 1.27)	0.88	0.94 (0.83 to 1.05)	0.26	0.52
5q33.3	rs1432679	158244083		A	G	No	0.45	1.01 (0.95 to 1.07)	0.79	0.92 (0.81 to 1.04)	0.16	1.04 (0.97 to 1.11)	0.30	0.09
6p25.3	rs11242675	1318878	<i>FOXQ1</i>	A	G	No	0.36	1.01 (0.95 to 1.07)	0.79	1.02 (0.89 to 1.18)	0.75	1.00 (0.93 to 1.08)	0.90	0.83
6p24.3	rs9348512	10456706	<i>TFAP2A</i>	C	A	Yes	0.34	0.85 (0.8 to 0.9)	9.2 × 10⁻⁸	0.79 (0.69 to 0.91)	1.1 × 10⁻³	0.86 (0.8 to 0.92)	3.4 × 10⁻⁵	0.32
6p23	rs204247	13722523	<i>RANBP9</i>	A	G	No	0.44	1.09 (1.03 to 1.15)	3.4 × 10⁻³	1.08 (0.94 to 1.24)	0.25	1.09 (1.02 to 1.17)	9.7 × 10⁻³	0.93
6q14	rs17530068	82193109	<i>FAM46A</i>	A	G	Yes	0.25	1.10 (1.03 to 1.18)	7.2 × 10⁻³	1.07 (0.92 to 1.25)	0.40	1.11 (1.02 to 1.2)	0.01	0.70
6q25.1	rs3757318	151914113	<i>ESR1</i>	G	A	Yes	0.09	1.15 (1.03 to 1.28)	0.01	1.33 (1.07 to 1.65)	9.1 × 10⁻³	1.09 (0.96 to 1.24)	0.17	0.12
6q25.1	rs2046210	151948366	<i>ESR1</i>	G	A	Yes	0.37	1.06 (0.99 to 1.12)	0.07	1.15 (1.00 to 1.33)	0.04	1.03 (0.96 to 1.1)	0.43	0.17

Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancer^a

7q35	rs720475	144074929	<i>ARHGEF5</i>	G	A	Yes	0.26	0.99 (0.92 to 1.06)	0.71	0.94 (0.80 to 1.09)	0.41	1.00 (0.93 to 1.08)	0.96	0.45
8p12	rs9693444	29509616	<i>DUSP4</i>	C	A	Yes	0.33	0.98 (0.93 to 1.05)	0.61	0.92 (0.80 to 1.07)	0.28	1.00 (0.94 to 1.07)	0.94	0.32
8q21.11	rs6472903	76230301		A	C	Yes	0.16	0.97 (0.90 to 1.05)	0.48	0.95 (0.79 to 1.14)	0.56	0.98 (0.89 to 1.07)	0.66	0.75
8q21.11	rs2943559	76417937	<i>HNF4G</i>	A	G	Yes	0.09	1.10 (1.00 to 1.22)	0.05	1.14 (0.91 to 1.43)	0.27	1.09 (0.97 to 1.23)	0.13	0.77
8q24.21	rs11780156	129194641	<i>MYC</i>	G	A	No	0.19	0.97 (0.90 to 1.04)	0.44	0.95 (0.81 to 1.12)	0.56	0.98 (0.9 to 1.06)	0.60	0.79
8q24.21	rs13281615	128355618		A	G	Yes	0.43	1.03 (0.97 to 1.09)	0.33	1.05 (0.92 to 1.20)	0.44	1.02 (0.96 to 1.1)	0.51	0.71
9p21.3	rs1011970	22062134	<i>CDKN2B</i>	C	A	Yes	0.17	1.03 (0.95 to 1.11)	0.50	1.11 (0.94 to 1.32)	0.21	1.00 (0.92 to 1.1)	0.95	0.29
9q31.2	rs10759243	110306115	<i>KLF4</i>	C	A	No	0.29	1.00 (0.94 to 1.06)	0.94	0.94 (0.81 to 1.09)	0.40	1.01 (0.94 to 1.09)	0.69	0.37
9q31.2	rs865686	110888478	<i>KLF4</i>	A	C	Yes	0.36	0.99 (0.93 to 1.05)	0.75	1.16 (1.01 to 1.34)	0.04	0.94 (0.88 to 1.01)	0.12	0.01
10p12.31	rs7072776	22032942	<i>MLLT10</i>	G	A	No	0.3	0.99 (0.92 to 1.05)	0.67	0.88 (0.77 to 1.02)	0.08	1.02 (0.94 to 1.09)	0.66	0.09
10p12.31	rs11814448	22315843	<i>DNAJC1</i>	A	C	No								
10q21.2	rs10995190	64278682	<i>ZNF365</i>	G	A	Yes	0.15	0.94 (0.86 to 1.02)	0.16	0.92 (0.76 to 1.12)	0.43	0.95 (0.86 to 1.04)	0.26	0.84
10q22.3	rs704010	80841148	<i>ZMIZ1</i>	G	A	Yes	0.38	1.01 (0.95 to 1.07)	0.86	1.02 (0.90 to 1.16)	0.78	1.00 (0.93 to 1.07)	0.96	0.83
10q25.2	rs7904519	114773927	<i>TCF7L2</i>	A	G	Yes	0.47	1.02 (0.96 to 1.08)	0.56	0.89 (0.78 to 1.01)	0.07	1.06 (0.99 to 1.13)	0.10	0.02
10q26.12	rs2981579	123337335	<i>FGFR2</i>	G	A	Yes	0.44	1.24 (1.16 to 1.31)	5.4×10^{-12}	1.05 (0.92 to 1.20)	0.44	1.29 (1.21 to 1.38)	2.2×10^{-13}	7.3×10^{-3}
10q26.12	rs11199914	123093901	<i>FGFR2</i>	G	A	No	0.33	0.95 (0.90 to 1.02)	0.15	0.90 (0.78 to 1.03)	0.13	0.97 (0.9 to 1.04)	0.44	0.33
11p15.5	rs3817198	1909006	<i>LSP1</i>	A	G	Yes	0.34	1.11 (1.04 to 1.18)	9.3×10^{-4}	0.98 (0.85 to 1.13)	0.80	1.15 (1.07 to 1.24)	1.1×10^{-4}	0.06
11q13.1	rs3903072	65583066	<i>SNX32</i>	C	A	No	0.47	0.97 (0.91 to 1.03)	0.34	0.89 (0.78 to 1.01)	0.07	1.00 (0.93 to 1.07)	0.91	0.12
11q13.3	rs554219	69331642	<i>CCND1</i>	C	G	Yes	0.13	1.09 (1.00 to 1.19)	0.05	0.90 (0.73 to 1.10)	0.31	1.15 (1.04 to 1.26)	5.0×10^{-3}	0.04
11q13.3	c11_pos69088342	69379161		C	A	Yes	0.06	1.07 (0.95 to 1.21)	0.28	0.85 (0.64 to 1.14)	0.29	1.14 (0.99 to 1.3)	0.08	0.09
11q13.3	rs494406	69344241		G	A	Yes	0.26	1.05 (0.98 to 1.12)	0.16	1.03 (0.89 to 1.19)	0.66	1.05 (0.98 to 1.14)	0.18	0.80
11q24.3	rs11820646	129461171	<i>BARX2</i>	G	A	No	0.39	0.92 (0.86 to 0.97)	4.2×10^{-3}	0.95 (0.83 to 1.09)	0.45	0.91 (0.84 to 0.97)	5.9×10^{-3}	0.56
12p13.1	rs12422552	14413931	<i>ATF7IP</i>	G	C	No	0.28	1.00 (0.93 to 1.06)	0.92	1.02 (0.88 to 1.19)	0.79	0.99 (0.92 to 1.07)	0.79	0.73
12p11.22	rs10771399	28155080	<i>PTHLH</i>	A	G	Yes	0.1	0.89 (0.81 to 0.98)	0.02	0.72 (0.56 to 0.91)	6.6×10^{-3}	0.94 (0.84 to 1.05)	0.25	0.05
12q22	rs17356907	96027759	<i>NTN4</i>	A	G	No	0.3	0.99 (0.93 to 1.06)	0.78	0.95 (0.83 to 1.10)	0.51	1.00 (0.93 to 1.08)	0.96	0.55
12q24.21	rs1292011	115836522	<i>TBX3</i>	A	G	Yes	0.41	0.92 (0.87 to 0.98)	0.01	1.07 (0.94 to 1.23)	0.29	0.88 (0.82 to 0.95)	5.7×10^{-4}	0.01
13q13.1	rs11571833	32972626	<i>BRCA2</i>	T	A	No	0.03	0.95 (0.78 to 1.16)	0.62	0.91 (0.58 to 1.41)	0.66	0.97 (0.78 to 1.2)	0.76	0.80
14q13.3	rs2236007	37132769	<i>PAX9</i>	G	A	No	0.21	0.99 (0.92 to 1.07)	0.83	1.20 (1.03 to 1.40)	0.02	0.94 (0.86 to 1.02)	0.13	8.5×10^{-3}
14q24.1	rs2588809	68660428		G	A	No	0.2	1.01 (0.94 to 1.09)	0.82	0.95 (0.80 to 1.13)	0.55	1.03 (0.94 to 1.12)	0.55	0.44
14q24.1	rs999737	69034682	<i>RADS1L1</i>	G	A	Yes	0.22	0.97 (0.91 to 1.05)	0.48	0.95 (0.81 to 1.11)	0.53	0.98 (0.91 to 1.06)	0.65	0.72
14q32.11	rs941764	91841069	<i>CCDC88C</i>	A	G	No	0.34	1.03 (0.97 to 1.09)	0.39	1.00 (0.88 to 1.14)	0.97	1.04 (0.97 to 1.11)	0.32	0.61
16q12.1a	rs3803662	52586341	<i>TOX3</i>	G	A	Yes	0.29	1.24 (1.16 to 1.32)	6.2×10^{-11}	1.12 (0.97 to 1.30)	0.11	1.27 (1.18 to 1.36)	1.5×10^{-10}	0.15
16q12.1b	rs11075995	53855291	<i>FTO</i>	A	T	No	0.24	1.02(0.95 to 1.09)	0.59	1.01 (0.86 to 1.18)	0.94	1.02 (0.94 to 1.11)	0.57	0.85

Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancer^a

16q12.1b	rs17817449	53813367	<i>FTO</i>	A	C	No	0.41	0.94 (0.88 to 1.00)	0.03	1.05 (0.91 to 1.21)	0.49	0.91 (0.85 to 0.97)	6.6 × 10⁻³	0.08
16q23.2	rs13329835	80650805	<i>CDYL2</i>	A	G	No	0.24	1.03 (0.96 to 1.11)	0.35	0.94 (0.81 to 1.10)	0.43	1.06 (0.98 to 1.15)	0.13	0.17
17q22	rs6504950	53056471	<i>COX11</i>	G	A	Yes	0.27	1.04 (0.97 to 1.11)	0.24	1.08 (0.94 to 1.24)	0.27	1.03 (0.95 to 1.11)	0.46	0.54
18q11.2	rs527616	24337424	<i>AQP4</i>	C	G	No	0.37	0.96 (0.9 to 1.02)	0.19	0.95 (0.83 to 1.08)	0.41	0.96 (0.9 to 1.03)	0.30	0.82
18q11.2	rs1436904	22824665		A	C	No	0.39	0.96 (0.9 to 1.02)	0.14	1.02 (0.89 to 1.17)	0.79	0.94 (0.87 to 1.01)	0.07	0.30
19p13.11	rs8170	17389704	<i>BABAM1</i>	G	A	Yes	0.19	0.98 (0.91 to 1.06)	0.62	1.06 (0.90 to 1.25)	0.51	0.96 (0.88 to 1.05)	0.37	0.33
19p13.11	rs4808801	18571141	<i>ELL</i>	A	G	No	0.33	0.97 (0.91 to 1.03)	0.33	1.07 (0.93 to 1.23)	0.33	0.94 (0.87 to 1.01)	0.10	0.11
19q13.31	rs3760982	44286513	<i>KCNN4</i>	G	A	No	0.46	1.05 (0.99 to 1.12)	0.09	0.97 (0.86 to 1.11)	0.69	1.08 (1.01 to 1.15)	0.03	0.19
21q21.1	rs2823093	16520832	<i>NRIP1</i>	G	A	Yes	0.27	0.94 (0.88 to 1.01)	0.09	1.07 (0.92 to 1.25)	0.36	0.91 (0.84 to 0.98)	0.02	0.06
22q12.2	rs132390	29621477	<i>EMID1</i>	A	G	No	0.04	1.17 (1.00 to 1.37)	0.05	0.92 (0.61 to 1.39)	0.70	1.24 (1.04 to 1.49)	0.02	0.22
22q13.1	rs6001930	40876234	<i>SGSM3</i>	A	G	No	0.10	1.02 (0.92 to 1.12)	0.71	0.94 (0.76 to 1.18)	0.61	1.04 (0.93 to 1.16)	0.48	0.44

^aCI, Confidence interval; ER, Estrogen receptor; HR, Hazard ratio; MAF, Mean allele frequency; SNP, Single-nucleotide polymorphism. Results represent *BRCA1* and *BRCA2* mutation carriers for 74 previously reported breast cancer (BC) susceptibility variants from population-based studies. *P*-values <0.05 are shown in bold. ^bPosition in build 37. ^cReference allele. ^dEffect allele. ^eAssociation in *BRCA1* and *BRCA2* carriers has been reported before. ^f*P*-value for the difference between the association with ER-positive BC and the association with ER-negative BC.

Table 3 Comparisons between the associations of 74 breast cancer susceptibility loci in *BRCA1* carriers, in *BRCA2* carriers, and in population-based studies^a

		<i>BRCA1</i> carriers			<i>BRCA2</i> carriers		
		Overall	ER-positive	ER-negative	Overall	ER-positive	ER-negative
<i>BRCA2</i> carriers	Overall	0.46 (0.25 to 0.62)					
	ER-positive		0.67 (0.52 to 0.78)	0.13 (-0.10 to 0.35)			
	ER-negative		0.10 (-0.13 to 0.33)	0.46 (0.25 to 0.62)			
BCAC	Overall	0.43 (0.22 to 0.60)			0.63 (0.47 to 0.75)		
	ER-positive		0.61 (0.45 to 0.74)	0.16 (-0.07 to 0.38)		0.69 (0.55 to 0.79)	0.13 (-0.11 to 0.35)
	ER-negative		0.34 (0.12 to 0.53)	0.59 (0.42 to 0.72)		0.39 (0.17 to 0.57)	0.28 (0.05 to 0.48)

^aER, Estrogen receptor. Data are intraclass correlation coefficients and 95% confidence intervals, which describe associations with overall breast cancer as well as by ER status. Data are derived from published studies by the Breast Cancer Association Consortium (BCAC).

0.72) (Figure 1E). However, the ER-negative breast cancer log HR estimates in *BRCA2* carriers were less strongly correlated with the corresponding estimates in *BRCA1* carriers (ICC = 0.46, 95% CI: 0.25 to 0.62) (Figure 1D) and in BCAC (ICC = 0.28, 95% CI: 0.05 to 0.48) (Figure 1F). There was no evidence that the ICC was different from 0 for the comparison between ER-positive associations in *BRCA1* carriers with ER-negative associations in *BRCA2* carriers and vice versa (Additional file 1: Figure S4B,C). Similarly, there was no significant correlation between log OR estimates for ER-positive breast cancer in BCAC with log HR estimates for ER-negative breast cancer in *BRCA1* and *BRCA2* carriers (Additional file 1: Figures S5B and S6B). There was only moderate correlation between log OR estimates for ER-negative breast cancer in the general population and log HR estimates for ER-positive breast cancer in *BRCA1* and *BRCA2* carriers (ICC = 0.39 and ICC = 0.34, respectively) (Additional file 1: Figures S5C and S6C).

Associations by subtype with all single-nucleotide polymorphisms on iCOGS

Variants in or near the known breast cancer susceptibility loci *TERT*, *ESR1* and 19p13.11 showed strong associations ($P < 10^{-6}$) with at least one of the categories in all subtype analyses in *BRCA1* carriers. The same was true for SNPs in *FGFR2* and *TOX3* in *BRCA2* carriers.

Variants on the iCOGS array that exhibited associations at $P < 10^{-6}$ with any of the breast cancer subtypes of ER-, PR-, HER2-positive or -negative and TN breast tumors are shown in Table 4. All the variants associated with ER-positive or ER-negative breast cancer at $P < 10^{-6}$ were located within known breast cancer susceptibility loci. Similar associations were observed with PR-positive and PR-negative breast cancer for *BRCA1* carriers. A previously unreported SNP at 2p13.2 was associated with HER2-positive breast cancer in *BRCA1* carriers. In *BRCA2* carriers, two previously unreported variants showed evidence of association in the analysis by PR status.

Furthermore, SNPs at 8q12.1 near *TOX* were associated with HER2-positive cancer in *BRCA2* carriers. Only SNPs in the known breast cancer susceptibility loci *FGFR2* and *TOX3* were associated with non-TN breast cancer in *BRCA2* carriers, and none were associated with TN breast cancer at $P < 10^{-6}$.

A SNP at 7q36 was associated with ductal subtype for *BRCA1* carriers (Table 5). Two loci were associated with lobular breast cancer for *BRCA2* carriers: 11q23.3 and Xp11.23.

There was one novel association with high-grade tumors in *BRCA1* carriers (Table 6). Three previously unreported variants were associated with breast cancer nodal status in *BRCA1* carriers: SNPs at 4q24 in the *TET2* gene, at 5q32 in the *SH3RF2* gene and at 7p22 in an intron of *NXPH1*. For *BRCA2* carriers, only SNPs in *FGFR2* and *TOX3* exhibited associations at $P < 10^{-6}$ with breast cancer nodal status or histological grade.

Discussion

This is the first comprehensive report, to our knowledge, of the associations of genetic variants with risk of developing breast cancer by tumor subtypes in *BRCA1* and *BRCA2* carriers. We evaluated the associations with ER, PR and HER2 status; morphologic subtype (ductal or lobular); histological grade; and lymph node status.

Prior to this study, variants at five loci (5p15.33, 6q25.1, 11p15.5, 12p11.22 and 16q12.1) had been shown to be associated with breast cancer risk for both *BRCA1* and *BRCA2* carriers; variants at four additional loci were known to be associated with breast cancer risk for *BRCA1* carriers only (1q32.1, 10q25.2, 14q24.1 and 19p13.11); and variants at six additional loci were known to be associated with risk for *BRCA2* carriers (3p24.1, 5p12, 6p24.3, 10q26.12, 11q13 and 12q24.21) [6,7,10]. Among the 43 breast cancer susceptibility variants that had not previously been evaluated in mutation carriers, we observed six associations with breast cancer at




Figure 1 Estrogen receptor-positive and -negative log hazard ratio estimates in the general population and in *BRCA1* and *BRCA2* carriers. Dots represent the association of 74 previously reported breast cancer susceptibility single-nucleotide polymorphisms with estrogen receptor (ER)-positive breast cancer (A–C) and ER-negative breast cancer (D–F). (A) and (D) compare associations between *BRCA1* and *BRCA2* carriers, (B) and (E) between the general population and *BRCA1* carriers and (C) and (F) between the general population and *BRCA2* carriers. Association results for the general population were taken from reports published by the Breast Cancer Association Consortium (BCAC) [8-10,16].

Table 4 Associations with tumor subtypes^a

Subtype	Sample	SNP	Locus	Position ^b	Nearby gene	Ref ^c	Eff ^d	Reported ^e	Affected by subtype, <i>n</i> (MAF)			Positive		Negative		<i>P</i> _{het} -value ^f	
									Positive	Negative	Unknown	Number unaffected (MAF)	HR (95% CI)	<i>P</i> -value	HR (95% CI)		<i>P</i> -value
ER status	<i>BRCA1</i> carriers	rs10069690	5p15.33	1332790	<i>TERT</i>	G	A	Yes	819 (0.27)	2,635 (0.3)	4,331 (0.3)	7,449 (0.26)	1.09 (0.98 to 1.22)	0.09	1.24 (1.18 to 1.31)	2.7×10^{-15}	0.04
		rs2046210	6q25.1	151990059	<i>C6orf97</i>	G	A	Yes	819 (0.36)	2,639 (0.39)	4,338 (0.38)	7,453 (0.35)	1.04 (0.94 to 1.15)	0.42	1.2 (1.15 to 1.26)	2.8×10^{-13}	0.01
		rs2811708	9p21	21963422	<i>CDKN2A/B</i>	C	A	Yes	816 (0.24)	2,634 (0.31)	4,336 (0.28)	7,445 (0.28)	0.82 (0.73 to 0.91)	2.9×10^{-4}	1.13 (1.07 to 1.19)	7.3×10^{-6}	3.9×10^{-7}
	rs45631579	10q26	123328965	<i>FGFR2</i>	A	G	Yes	819 (0.48)	2,639 (0.4)	4,337 (0.42)	7,455 (0.41)	1.29 (1.17 to 1.43)	2.6×10^{-7}	0.92 (0.87 to 0.96)	4.7×10^{-4}	5.1×10^{-9}	
	rs2590275	12p12	28057334	<i>PTHLH</i>	G	C	Yes	819 (0.26)	2,639 (0.25)	4,338 (0.26)	7,454 (0.28)	0.92 (0.83 to 1.03)	0.14	0.87 (0.82 to 0.92)	5.3×10^{-7}	0.34	
	rs2363956	19p13.11	17255124	<i>ANKLE1</i>	C	A	Yes	819 (0.47)	2,635 (0.53)	4,334 (0.52)	7,447 (0.48)	0.98 (0.89 to 1.08)	0.71	1.25 (1.19 to 1.31)	6.4×10^{-20}	1.6×10^{-5}	
ER status	<i>BRCA2</i> carriers	rs2162540	10q26	123342126	<i>FGFR2</i>	A	G	Yes	1450 (0.47)	426 (0.41)	2,348 (0.44)	3,783 (0.38)	1.34 (1.25 to 1.43)	3.6×10^{-16}	1.08 (0.94 to 1.23)	0.27	6.1×10^{-3}
		rs17271951	16q12.1	51095541	<i>TOX3</i>	A	G	Yes	1490 (0.32)	434 (0.28)	2,397 (0.3)	3,879 (0.25)	1.29 (1.2 to 1.39)	8.4×10^{-12}	1.14 (0.99 to 1.31)	0.08	0.14
		rs10069690	5p15.33	1332790	<i>TERT</i>	G	A	Yes	662 (0.27)	2,481 (0.29)	4,642 (0.3)	7,449 (0.26)	1.10 (0.98 to 1.24)	0.09	1.24 (1.17 to 1.3)	1.3×10^{-14}	0.11
PR status	<i>BRCA1</i> carriers	rs2046210	6q25.1	151990059	<i>C6orf97</i>	G	A	Yes	662 (0.37)	2,485 (0.39)	4,649 (0.38)	7,453 (0.35)	1.09 (0.98 to 1.21)	0.12	1.18 (1.13 to 1.24)	2.0×10^{-11}	0.19
		rs45631626	10q26	123327325	<i>FGFR2</i>	G	A	Yes	662 (0.49)	2,485 (0.4)	4,647 (0.42)	7,455 (0.42)	1.33 (1.2 to 1.48)	1.3×10^{-7}	0.92 (0.88 to 0.97)	9.6×10^{-4}	5.3×10^{-9}
		rs2590275	12p12	28057334	<i>PTHLH</i>	G	C	Yes	662 (0.26)	2,485 (0.25)	4,649 (0.26)	7,454 (0.28)	0.92 (0.82 to 1.03)	0.16	0.87 (0.82 to 0.92)	8.2×10^{-7}	0.45
		rs8100241	19p13.11	17253894	<i>ANKLE1</i>	G	A	Yes	657 (0.51)	2,473 (0.47)	4,628 (0.48)	7,420 (0.52)	0.98 (0.88 to 1.09)	0.71	0.81 (0.78 to 0.85)	1.8×10^{-17}	2.4×10^{-3}
		rs10069690	5p15.33	1332790	<i>TERT</i>	G	A	Yes	662 (0.27)	2,481 (0.29)	4,642 (0.3)	7,449 (0.26)	1.10 (0.98 to 1.24)	0.09	1.24 (1.17 to 1.3)	1.3×10^{-14}	0.11

Table 4 Associations with tumor subtypes^a (Continued)

	<i>BRCA2</i> carriers	rs10017576	4q28.3	139799629	G	A	No	1099 (0.38)	591 (0.43)	2,639 (0.41)	3,880 (0.43)	0.83 (0.77 to 0.89)	8.9×10^{-7}	1.02 (0.92 to 1.14)	0.67	2.7×10^{-3}	
		rs4376461	8p12	32822117	<i>NRG1</i>	C	A	No	1099 (0.15)	591 (0.10)	2,640 (0.14)	3,881 (0.15)	1.00 (0.9 to 1.12)	0.93	0.6 (0.5 to 0.73)	2.4×10^{-7}	1.4×10^{-5}
		rs45631588	10q26	123341292	<i>FGFR2</i>	A	G	Yes	1099 (0.47)	591 (0.43)	2,640 (0.45)	3,881 (0.39)	1.33 (1.23 to 1.44)	2.7×10^{-13}	1.15 (1.03 to 1.28)	0.01	0.04
		rs17271951	16q12.1	51095541	<i>TOX3</i>	A	G	Yes	1099 (0.32)	591 (0.28)	2,631 (0.3)	3,879 (0.25)	1.32 (1.21 to 1.43)	4.3×10^{-11}	1.14 (1.01 to 1.29)	0.03	0.07
HER2 status	<i>BRCA1</i> carriers	rs17008885	2p13.2	73303647	<i>SMYD5</i>	T	A	No	182 (0.19)	1,816 (0.3)	5,799 (0.3)	7,455 (0.31)	0.54 (0.43 to 0.69)	7.8×10^{-7}	0.99 (0.95 to 1.04)	0.78	3.8×10^{-6}
		rs10069690	5p15.33	1332790	<i>TERT</i>	G	A	Yes	181 (0.23)	1,813 (0.29)	5,791 (0.3)	7,449 (0.26)	0.9 (0.71 to 1.13)	0.36	1.24 (1.18 to 1.3)	3.4×10^{-17}	0.01
		rs2046210	6q25.1	151990059	<i>C6orf97</i>	G	A	Yes	182 (0.39)	1,816 (0.4)	5,798 (0.38)	7,453 (0.35)	1.12 (0.91 to 1.38)	0.29	1.17 (1.11 to 1.22)	1.5×10^{-10}	0.71
		rs10843055	12p12	28063088	<i>PTHLH</i>	A	C	Yes	171 (0.06)	1,743 (0.06)	5,615 (0.06)	7,234 (0.07)	0.79 (0.52 to 1.2)	0.26	0.79 (0.72 to 0.87)	6.2×10^{-7}	0.99
		rs4808616	19p13.11	17264033	<i>ANKLE1</i>	C	A	Yes	176 (0.35)	1,782 (0.32)	5,706 (0.32)	7,339 (0.28)	1.37 (1.11 to 1.69)	3.8×10^{-3}	1.2 (1.14 to 1.26)	6.8×10^{-13}	0.25
	<i>BRCA2</i> carriers	rs4305889	8q12.1	60352785	<i>TOX</i>	A	G	No	121 (0.18)	845 (0.09)	3,353 (0.11)	3,874 (0.1)	2.04 (1.53 to 2.71)	8.7×10^{-7}	0.96 (0.85 to 1.08)	0.47	1.0×10^{-5}
		rs45631588	10q26	123341292	<i>FGFR2</i>	A	G	Yes	121 (0.45)	847 (0.46)	3,362 (0.45)	3,881 (0.39)	1.27 (0.98 to 1.63)	0.07	1.28 (1.19 to 1.37)	2.1×10^{-12}	0.95
		rs3817197	11p15.5	1862750	<i>LSP1</i>	G	A	Yes	121 (0.55)	847 (0.44)	3,353 (0.45)	3,877 (0.47)	1.30 (1.02 to 1.64)	0.03	0.84 (0.79 to 0.9)	9.1×10^{-7}	1.3×10^{-3}
		rs17271951	16q12.1	51095541	<i>TOX3</i>	A	G	Yes	121 (0.29)	847 (0.31)	3,353 (0.3)	3,879 (0.25)	1.10 (0.85 to 1.41)	0.47	1.27 (1.18 to 1.37)	6.9×10^{-11}	0.3

Table 4 Associations with tumor subtypes^a (Continued)

Triple-negative ^g	<i>BRCA1</i> carriers	rs10069690	5p15.33	1332790	<i>TERT</i>	G	A	Yes	579 (0.27)	1,307 (0.3)	5,899 (0.3)	7,449 (0.26)	1.06 (0.94 to 1.19)	0.34	1.27 (1.2 to 1.36)	5.2×10^{-14}	0.02
		rs2046210	6q25.1	151990059	<i>C6orf97</i>	G	A	Yes	580 (0.37)	1,310 (0.41)	5,906 (0.38)	7,453 (0.35)	1.01 (0.91 to 1.13)	0.79	1.23 (1.16 to 1.31)	5.5×10^{-12}	6.8×10^{-3}
		rs9512729	13q12.2	26974865	<i>LNX2</i>	G	A	No	580 (0.34)	1,309 (0.43)	5,902 (0.41)	7,454 (0.41)	0.76 (0.69 to 0.85)	9.1×10^{-7}	1.08 (1.02 to 1.15)	0.01	1.2×10^{-6}
		rs8100241	19p13.11	17253894	<i>ANKLE1</i>	G	A	Yes	577 (0.5)	1,304 (0.46)	5,877 (0.48)	7,420 (0.52)	0.94 (0.85 to 1.04)	0.22	0.81 (0.76 to 0.86)	2.4×10^{-13}	0.03
	<i>BRCA2</i> carriers	rs2162540	10q26	123342126	<i>FGFR2</i>	A	G	Yes	735 (0.46)	133 (0.36)	3,356 (0.44)	3,783 (0.38)	1.39 (1.29 to 1.49)	9.8×10^{-20}	0.83 (0.67 to 1.03)	0.10	4.0×10^{-5}
		rs1362548	16q12.1	51121452	<i>TOX3</i>	C	G	Yes	760 (0.32)	136 (0.29)	3,434 (0.31)	3,881 (0.26)	1.26 (1.17 to 1.36)	1.0×10^{-9}	1.18 (0.94 to 1.49)	0.16	0.63

^aCI, Confidence interval; HR, Hazard ratio; MAF, Mean allele frequency. Single-nucleotide polymorphisms (SNPs) associated at $P < 10^{-6}$ with breast cancer by tumor estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status or triple-negative (negative for ER, PR and HER2) are shown. The most strongly associated SNP from each locus is reported. ^bPosition in build 36. ^cReference allele. ^dEffect allele. ^eVariant located in previously reported breast cancer susceptibility locus. ^fP-value for the difference in association between subtype positive and subtype negative breast cancer (for example, ER-positive vs ER-negative). ^gNon-triple negative was considered as "positive" and triple-negative as "negative."

Table 5 Associations with ductal and lobular breast cancer^a

Subtype	Sample	SNP	Locus	Position ^b	Nearby gene	Ref ^c	Eff ^d	Reported ^e	N tumors with morphology (MAF)			Number unaffected (MAF)	Other morphology		Tumors with morphology		P_{het} -value ^f
									Present	Other	Unknown		HR (95% CI)	P-value	HR (95% CI)	P-value	
Ductal	<i>BRCA1</i> carriers	rs10069690	5p15.33	1332790	<i>TERT</i>	G	A	Yes	3,155 (0.29)	847 (0.30)	3,783 (0.30)	7,449 (0.26)	1.23 (1.11 to 1.36)	7.3×10^{-5}	1.20 (1.14 to 1.26)	2.0×10^{-11}	0.67
		rs11155803	6q25.1	151987362	<i>C6orf97</i>	A	G	Yes	3,159 (0.36)	848 (0.35)	3,786 (0.36)	7,452 (0.32)	1.13 (1.03 to 1.25)	0.01	1.17 (1.11 to 1.23)	4.6×10^{-10}	0.58
		rs10252939	7q36	155587448		A	G	No	3,159 (0.28)	849 (0.33)	3,789 (0.29)	7,455 (0.32)	1.08 (0.98 to 1.19)	0.14	0.87 (0.82 to 0.91)	1.0×10^{-7}	2.7×10^{-4}
	rs8100241	19p13.11	17253894	<i>ANKLE1</i>	G	A	Yes	3,137 (0.48)	844 (0.49)	3,777 (0.47)	7,420 (0.52)	0.87 (0.79 to 0.95)	2.8×10^{-3}	0.84 (0.8 to 0.88)	1.5×10^{-13}	0.51	
	<i>BRCA2</i> carriers	rs2162540	10q26	123342126	<i>FGFR2</i>	A	G	Yes	1,728 (0.45)	458 (0.44)	2,038 (0.44)	3,783 (0.38)	1.24 (1.08 to 1.42)	1.8×10^{-3}	1.30 (1.21 to 1.39)	3.1×10^{-14}	0.55
		rs1362548	16q12.1	51121452	<i>TOX3</i>	C	G	Yes	1,770 (0.3)	473 (0.32)	2,087 (0.31)	3,881 (0.26)	1.32 (1.15 to 1.51)	4.8×10^{-5}	1.23 (1.15 to 1.32)	7.3×10^{-9}	0.36
Lobular	<i>BRCA2</i> carriers	rs2186703	11q23.3	115265717	<i>RPL15P15</i>	A	C	No	188 (0.07)	2,055 (0.03)	2,087 (0.04)	3,881 (0.03)	1.09 (0.93 to 1.27)	0.29	2.54 (1.78 to 3.62)	2.8×10^{-7}	1.5×10^{-5}
		rs55998524	Xp11.23	51082075	<i>NUDT10</i>	C	G	No	188 (0.11)	2,054 (0.05)	2,086 (0.06)	3,880 (0.05)	0.96 (0.83 to 1.1)	0.54	2.42 (1.77 to 3.32)	3.6×10^{-8}	7.0×10^{-8}

^aCI, Confidence interval; HR, Hazard ratio; MAF, Mean allele frequency. Single-nucleotide polymorphisms (SNPs) associated at $P < 10^{-6}$ with ductal carcinomas and, for *BRCA2* mutation carriers, lobular carcinomas are shown. The most strongly associated SNP from each locus is reported. ^bPosition in build 36. ^cReference allele. ^dEffect allele. ^eVariant located in previously reported breast cancer susceptibility locus. ^fP-value for the difference in SNP association between ductal breast tumors and non-ductal breast tumors and for lobular breast tumors and non-lobular breast tumors.

Table 6 Associations with grade and lymph node status^a

Subtype	Sample	SNP	Locus	Position ^b	Nearby gene	Ref ^c	Eff ^d	Reported ^e	Affected by subtype, <i>n</i> (MAF)			Low-grade/ no nodal involvement		High grade/ nodal involvement		<i>P</i> _{het} -value ^f	
									High-grade/ node-positive	Low-grade/ node-negative	Unknown	Number unaffected (MAF)	HR (95% CI)	<i>P</i> -value	HR (95% CI)		<i>P</i> -value
Grade 3	<i>BRCA1</i> carriers	rs17651413	2q33.1	202677054	<i>KIAA2012</i>	A	G	No	2,495 (0.12)	655 (0.11)	4,644 (0.13)	7,454 (0.11)	1.01 (0.86 to 1.2)	0.86	1.20 (1.12 to 1.29)	8.4×10^{-7}	0.08
		rs10069690	5p15.33	1332790	<i>TERT</i>	G	A	Yes	2,493 (0.3)	654 (0.29)	4,638 (0.3)	7,449 (0.26)	1.15 (1.02 to 1.29)	0.02	1.22 (1.16 to 1.29)	2.4×10^{-13}	0.39
		c6_pos151989450	6q25.1	151989450	<i>C6orf97</i>	G	A	Yes	2,497 (0.11)	655 (0.08)	4,645 (0.1)	7,455 (0.08)	1.01 (0.83 to 1.24)	0.91	1.31 (1.21 to 1.42)	2.2×10^{-11}	0.02
		rs8100241	19p13.11	17253894	<i>ANKLE1</i>	G	A	Yes	2,483 (0.48)	653 (0.52)	4,622 (0.48)	7,420 (0.52)	0.95 (0.86 to 1.05)	0.36	0.82 (0.78 to 0.86)	2.2×10^{-16}	0.01
	<i>BRCA2</i> carriers	rs45631588	10q26	123341292	<i>FGFR2</i>	A	G	Yes	839 (0.44)	813 (0.48)	2,678 (0.44)	3,881 (0.39)	1.36 (1.24 to 1.49)	7.4×10^{-11}	1.19 (1.09 to 1.3)	1.7×10^{-4}	0.06
		rs35850695	16q12.1	51131844	<i>TOX3</i>	G	A	Yes	839 (0.32)	813 (0.3)	2,678 (0.3)	3,881 (0.26)	1.2 (1.09 to 1.33)	3.0×10^{-4}	1.31 (1.19 to 1.44)	4.0×10^{-8}	0.26
Nodes	<i>BRCA1</i> carriers	rs1498125	4q24	106412012	<i>TET2</i>	A	G	No	1,103 (0.2)	2,274 (0.23)	4,419 (0.22)	7,455 (0.2)	1.18 (1.1 to 1.25)	4.4×10^{-7}	0.98 (0.89 to 1.09)	0.74	5.7×10^{-3}
		rs10069690	5p15.33	1332790	<i>TERT</i>	G	A	Yes	1,100 (0.3)	2,271 (0.29)	4,414 (0.3)	7,449 (0.26)	1.19 (1.12 to 1.26)	6.2×10^{-9}	1.24 (1.13 to 1.35)	2.0×10^{-6}	0.5
		rs11743632	5q32	145389263	<i>SH3RF2</i>	G	A	No	1,103 (0.31)	2,274 (0.37)	4,418 (0.36)	7,453 (0.37)	1.05 (0.99 to 1.11)	0.1	0.8 (0.74 to 0.87)	2.3×10^{-7}	6.9×10^{-7}
		rs9383936	6q25.1	151986307	<i>C6orf97</i>	G	A	Yes	1,103 (0.11)	2,274 (0.09)	4,420 (0.1)	7,455 (0.08)	1.16 (1.06 to 1.28)	1.3×10^{-3}	1.41 (1.24 to 1.6)	1.3×10^{-7}	0.03

Table 6 Associations with grade and lymph node status^a (Continued)

	rs2349485	7p22	8517481	<i>NXPH1</i>	A	C	No	1,091 (0.37)	2,249 (0.34)	4,374 (0.34)	7,398 (0.37)	0.87 (0.82 to 0.92)	8.5×10^{-7}	0.97 (0.90 to 1.06)	0.53	0.03
	rs11669059	19p13.11	17261453	<i>ANKLE1</i>	A	G	Yes	1,103 (0.41)	2,273 (0.4)	4,418 (0.39)	7,452 (0.43)	0.85 (0.81 to 0.9)	2.9×10^{-9}	0.86 (0.80 to 0.93)	2.6×10^{-4}	0.81
<i>BRCA2</i> carriers	rs2981578	10q26	123330301	<i>FGFR2</i>	A	G	Yes	795 (0.44)	1,047 (0.48)	2,428 (0.47)	3,819 (0.52)	0.87 (0.8 to 0.94)	7.4×10^{-4}	0.75 (0.68 to 0.82)	1.0×10^{-9}	0.02
	rs35850695	16q12.1	51131844	<i>TOX3</i>	G	A	Yes	804 (0.31)	1,068 (0.3)	2,458 (0.3)	3,881 (0.26)	1.22 (1.12 to 1.33)	8.5×10^{-6}	1.30 (1.18 to 1.44)	2.6×10^{-7}	0.36

^aCI, Confidence interval; HR, Hazard ratio; MAF, Mean allele frequency. Single-nucleotide polymorphisms (SNPs) associated at $P < 10^{-6}$ with high- or low-grade breast tumors and lymph node-positive or lymph node-negative breast cancer are shown. The most strongly associated SNPs from each locus are reported. ^bPosition in build 36. ^cReference allele. ^dEffect allele. ^eVariant located in previously reported breast cancer susceptibility locus. ^f P -value for the difference in association between high-grade breast cancer and low-grade breast cancer for grade 3 and for the association with lymph node-positive breast cancer and lymph node-negative breast cancer.

$P < 0.05$ in *BRCA1* carriers (5p33.3, 8q24.21, 11q24.3, 12q22, 16q12.1b and 22q13.1) and three in *BRCA2* carriers (6p23, 11q24.3 and 16q12.1b).

After stratifying by ER status, we observed additional associations that were not seen for overall breast cancer. Among the 43 susceptibility variants that were evaluated in mutation carriers for the first time, we identified two additional associations in *BRCA1* carriers when stratifying by ER status (3q26.1, 6p25.3) and four in *BRCA2* carriers (2q24, 14q13.3, 19q13.3, 22q12.2). Population-based studies have shown that seven of the 74 breast cancer susceptibility variants display stronger associations with ER-negative disease in the general population [9]. Consistent with these findings, SNPs at 1q32.1 (*MDM4*), 5p15.33, 6q25.1 and 19p13 were associated with ER-negative breast cancer in *BRCA1* carriers and SNPs at 2p24.1, 5p15.33 and 6q25.1 in *BRCA2* carriers. No data were available for the SNP at 20q11.

We were able to confirm most of the associations with ER and PR subtypes of the 12 SNPs reported in the previous smaller CIMBA study [15]. In addition, two variants from that analysis now displayed evidence at $P < 0.05$: rs13387042 at 2q35 with ER-positive breast cancer in *BRCA1* carriers and rs2046210 at 6q25.1 with ER-negative breast cancer in *BRCA2* carriers.

We also evaluated the associations of the 74 previously reported breast cancer susceptibility loci with other breast cancer subtypes. Variants at 5p15.33 (*TERT*), 6q25.1 (*ESR1*) and 19p13.11 showed associations in all subtype analyses for *BRCA1* carriers. These are the most strongly associated loci for overall breast cancer in *BRCA1* carriers, but they had not previously been investigated for their roles in subtypes other than ER. Variants at these three loci were associated with ER-, PR- and HER2-negative and TN subtypes. These variants were also associated with risk of high-grade tumors, with some suggestive evidence that this association was different from the association with grades 1 and 2 tumors for SNPs at *ESR1* and 19p13. The three loci were associated with ductal as well as non-ductal subtypes and node-positive as well as node-negative breast cancer. For *BRCA2* carriers, SNPs at loci 10q26 (*FGFR2*) and 16q12.1 (*TOX3*) were associated with all subtypes of breast cancer. SNPs at *FGFR2* and *TOX3* have consistently been associated with overall and with ER-positive breast cancer in population-based cases [25] as well as in *BRCA1/2* carriers [15]. Furthermore, SNPs at these two loci were associated with PR-positive and HER2-negative disease. There was no evidence for a difference in HR estimates by tumor grade, nodal involvement or morphologic subtype (ductal).

It is important to note that for each of the 74 known loci considered, we evaluated only the associations for the specific SNPs that have been reported by the BCAC. We have not considered all genetic variants within a

given region. Therefore, we cannot rule out the possibility that more strongly associated variants exist at these loci than the SNPs reported here. Future fine-mapping efforts in conjunction with BCAC analyses should clarify this. Such studies may also identify the causal variant and together with subsequent functional studies gather insights about the functional mechanisms causing these association signals. This in turn may yield insights about the etiology of breast cancer in *BRCA1* and *BRCA2* carriers.

We compared HRs for the association with overall breast cancer and ER-positive and ER-negative breast cancer for all the 74 known breast cancer susceptibility variants between *BRCA1* carriers, *BRCA2* carriers and population-based studies using published data from BCAC. Although only some of these variants were associated at $P < 0.05$ with breast cancer in mutation carriers as outlined above, there was nevertheless strong correlation between the HRs for overall breast cancer from the general population and those from *BRCA2* carriers, and moderate correlation between the HRs from *BRCA1* carriers and from BCAC. These results suggest that many of these variants may also be associated with breast cancer risk for mutation carriers, but the power to detect statistically significant associations in mutation carriers is low. These variants could be employed in risk prediction models for mutation carriers. Future studies should be aimed at assessing the associations of the combined effects of the SNPs in mutation carriers in terms of polygenic risk scores.

We used these comparisons to assess the hypothesis that observed differences in the associations between *BRCA1* and *BRCA2* carriers and the general population are mediated by ER status. The smaller correlation between the association estimates for *BRCA1* carriers and both BCAC and *BRCA2* carriers compared with those between BCAC and *BRCA2* carriers is consistent with this hypothesis. Moreover, we found stronger correlations between the HRs for ER-positive disease in all three two-way comparisons (ICC = 0.61 to 0.69). The correlation between ORs for ER-negative disease from BCAC and HRs for ER-negative disease from *BRCA1* carriers was also strong (ICC = 0.59). Correlations diminished when comparing HR estimates for ER-positive with estimates for ER-negative breast cancer; most of them were not significantly different from zero. This finding suggests that, to a large extent, the difference in SNP association patterns is due to mediating effects of tumor ER status. Under such a model, the effects of common breast cancer susceptibility variants and of *BRCA1* and *BRCA2* mutations on breast cancer risk would be multiplicative, after taking into account tumor ER status. As *BRCA1* carriers are more likely to develop ER-negative disease, SNPs associated with this subtype will be more

informative in models to predict overall breast cancer risk in these women, whereas SNPs associated with ER-positive disease will be more useful in *BRCA2* carriers. Furthermore, ER-specific SNP associations could be used to provide separate estimates of ER-negative and ER-positive breast cancer risk for mutation carriers. This understanding allows the development of more refined models and is critical to the provision of accurate information to women considering more targeted preventive options.

However, the fact that the correlations between the HR estimates matched for ER status were smaller than 1 implies that there were still some differences in the associations after accounting for ER status. This could be due to sampling error or to real differences in genetic associations between *BRCA1* and *BRCA2* carriers and the general population. There are examples for such differences: *BRCA1* and *BRCA2* carrier-specific modifiers, such as the recently identified variant at 6p24, which was associated with breast cancer risk only in *BRCA2* carriers [6], and the ovarian cancer susceptibility locus 4q32, which appeared to modify ovarian cancer risk only for *BRCA1* carriers [7]. In addition, an ovarian cancer susceptibility locus 17q11.2 identified through population-based data has been shown to display a consistent association in *BRCA2* carriers, whereas an association of similar magnitude has been ruled out in *BRCA1* carriers [26]. The extent to which genetic susceptibility to breast cancer in mutation carriers and in the general population is shared, as well as the extent to which it is mediated by ER status, need to be quantified systematically by future studies.

We also assessed the associations of over 200,000 SNPs on the iCOGS array. We identified several variants not previously reported that were associated with breast cancer at $P < 10^{-6}$ in the analyses by PR status, HER status, TN phenotype, histological grade, nodal involvement, ductal and lobular morphologic subtypes. In the absence of P -values at genome-wide significance levels for these associations to account for multiple testing, these associations require confirmation through by gathering additional data.

Although this is the largest study of its kind, the statistical power to detect associations of variants conferring small effects with specific tumor characteristics may be low, owing to the limited data available. Future studies of additional *BRCA1* and *BRCA2* carriers with detailed tumor pathology information on new and previously recruited mutation carriers are needed. In this study, tumor pathology information was retrieved primarily from medical records. Despite extensive efforts, it is difficult to control the quality of these data. If there is low reproducibility in the classification of tumor characteristics for some samples, this could potentially add to the sampling error and make it more difficult to detect subtype-specific associations.

Conclusions

We have identified additional genetic modifiers of breast cancer risk for mutation carriers among reported breast cancer susceptibility loci. Large differences in absolute risk are expected between mutation carriers who carry many and mutation carriers who carry few risk alleles of modifying variants [6,7]. Therefore, in combination with previously identified modifiers, these variants may be of value for cancer risk prediction. Moreover, our results show that, to a large extent, the differences in breast cancer associations of known breast cancer susceptibility loci between *BRCA1* and *BRCA2* carriers and the general population are due to differences in the prevalence of tumor subtypes in *BRCA1* and *BRCA2* carriers. Estimates of the risks associated with these genetic variants based on large population-based association studies are likely to be applicable also to mutation carriers after taking ER status into account. Our results thus have implications for developing risk prediction models for breast cancer subtype-specific risks in mutation carriers that incorporate the effects of these SNPs.

Additional file

Additional file 1: Table S1. Ethics committees that granted approval for the access and use of the data for this study. **Table S2.** Hormone receptor definitions used by the studies. **Table S3.** Associations of breast cancer susceptibility variants with breast cancer by tumor ER status after excluding prevalent cases. **Table S4.** Associations of breast cancer susceptibility variants with breast cancer by tumor PR status. **Table S5.** Associations of breast cancer susceptibility variants with breast cancer by tumor HER2 status. **Table S6.** Associations of breast cancer susceptibility variants with breast cancer by tumor triple-negative status. **Table S7.** Associations of breast cancer susceptibility variants with ductal breast cancer. **Table S8.** Associations of breast cancer susceptibility variants with lobular breast cancer. **Table S9.** Associations of breast cancer susceptibility variants with breast cancer by tumor grade. **Table S10.** Associations of breast cancer susceptibility variants with breast cancer by nodal involvement. **Figure S1.** QQ plots for SNP associations with ER-positive and -negative breast cancer in *BRCA1* carriers. **Figure S2.** QQ plots for SNP associations with ER-positive and -negative breast cancer in *BRCA2* carriers. **Figure S3.** Comparison of the breast cancer associations of breast cancer susceptibility loci in BCAC and in *BRCA1* and *BRCA2* carriers. **Figure S4.** Comparison of the associations of breast cancer susceptibility loci by ER status in *BRCA1* and in *BRCA2* carriers. **Figure S5.** Comparison of the associations of breast cancer susceptibility loci by ER status in population-based studies (BCAC) and in *BRCA1* carriers. **Figure S6.** Comparison of the associations of breast cancer susceptibility loci by ER status in population-based studies (BCAC) and in *BRCA2* carriers.

Abbreviations

BC: Breast cancer; BCAC: Breast Cancer Association Consortium; CIMBA: Consortium of Investigators of Modifiers of *BRCA1/2*; ER: Estrogen receptor; GWAS: Genome-wide association study; HER2: Human epidermal growth factor receptor 2; HR: Hazard ratio; ICC: Intraclass correlation; OR: Odds ratio; PR: Progesterone receptor; SNP: Single-nucleotide polymorphism; TN: Triple-negative.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

KBK, ACA, SLN, MR drafted the initial manuscript. KBK performed the statistical analyses. ACA, SLN, MR, AMM, DB, LM, KBK, ILA, ABS, MKS, RKS, CE, BW, HN, MT, MS, PR, SJR, SMD and FJC are members of the CIMBA pathology working group and participated in the design of the study. LM and DB are the CIMBA database managers. GCT initiated and coordinated CIMBA. All authors except KBK, DB, LM and AL acquired phenotypic data and DNA samples or performed SNP genotyping. All authors read and approved the final manuscript.

Acknowledgements

This study would not have been possible without the contributions of the following people: Per Hall (COGS); Paul Pharoah, Kyriaki Michailidou, Manjeet K Bolla, Qin Wang (BCAC), Andrew Berchuck (OCAC), Rosalind A Eeles, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Alison M Dunning, Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Daniel C Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of McGill University and Génomique Québec Innovation Centre, Stig E Bojesen, Sune F Nielsen, Borge G Nordestgaard, and the staff of the Copenhagen DNA laboratory, Sharon A Windebank, Christopher A Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility; Maggie Angelakos, Judi Maskiell, Gillian Dite, Helen Tsimiklis; members and participants in the New York site of the Breast Cancer Family Registry; members and participants in the Ontario Familial Breast Cancer Registry; Vilius Rudaitis, Laimonas Griškevičius, Drs Janis Eglitis, Anna Krilova and Aivars Stengrevics; the families who contribute to the MBMSA study; Yuan Chun Ding and Linda Steele; Alicia Barroso, Rosario Alonso and Guillermo Pita; Monica Barile and Irene Feroce of the Istituto Europeo di Oncologia, Milan, Italy; Alessandra Viel of the Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Laura Ottini of the "Sapienza" University, Rome, Italy; Antonella Savarese and Aline Martayan of the Istituto Nazionale Tumori Regina Elena, Rome, Italy; Stefania Tommasi and Brunella Pilato of the Istituto Nazionale Tumori "Giovanni Paolo II", Bari, Italy; Loris Bernard and the personnel of the Cogentech Cancer Genetic Test Laboratory, Milan, Italy. The EMBRACE Collaborating Centers are: Coordinating Centre, Cambridge: Debra Frost, Steve Ellis, Radka Platte, Jo Perkins; North of Scotland Regional Genetics Service, Aberdeen: Zosia Miedzzybrodzka, Helen Gregory; Northern Ireland Regional Genetics Service, Belfast: Patrick Morrison, Lisa Jeffers; West Midlands Regional Clinical Genetics Service, Birmingham: Trevor Cole, Kai-ren Ong, Jonathan Hoffman; South West Regional Genetics Service, Bristol: Alan Donaldson, Margaret James; East Anglian Regional Genetics Service, Cambridge: Marc Tischkowitz, Joan Paterson, Sarah Downing, Amy Taylor; Medical Genetics Services for Wales, Cardiff: Alexandra Murray, Mark T Rogers, Emma McCann; St James's Hospital, Dublin & National Centre for Medical Genetics, Dublin: M John Kennedy, David Barton; South East of Scotland Regional Genetics Service, Edinburgh: Mary Porteous, Sarah Drummond; Peninsula Clinical Genetics Service, Exeter: Carole Brewer, Emma Kivuva, Anne Searle, Selina Goodman, Kathryn Hill; West of Scotland Regional Genetics Service, Glasgow: Rosemarie Davidson, Victoria Murday, Nicola Bradshaw, Lesley Snadden, Mark Longmuir, Catherine Watt, Sarah Gibson, Eshika Haque, Ed Tobias, Alexis Duncan; South East Thames Regional Genetics Service, Guy's Hospital London: Louise Izatt, Chris Jacobs, Caroline Langman; North West Thames Regional Genetics Service, Harrow: Huw Dorkins; Leicestershire Clinical Genetics Service, Leicester: Julian Barwell; Yorkshire Regional Genetics Service, Leeds: Julian Adlard, Gemma Serra-Feliu; Cheshire & Merseyside Clinical Genetics Service, Liverpool: Ian Ellis, Claire Foo; Manchester Regional Genetics Service, Manchester: D Gareth Evans, Fiona Lalloo, Jane Taylor; North East Thames Regional Genetics Service, NE Thames, London: Lucy Side, Alison Male, Cheryl Berlin; Nottingham Centre for Medical Genetics, Nottingham: Jacqueline Eason, Rebecca Collier; Northern Clinical Genetics Service, Newcastle: Fiona Douglas, Oonagh Claber, Irene Jobson; Oxford Regional Genetics Service, Oxford: Lisa Walker, Diane McLeod, Dorothy Halliday, Sarah Durell, Barbara Stayner; the Institute of Cancer Research and Royal Marsden NHS Foundation Trust: Ros Eeles, Susan Shanley, Nazneen Rahman, Richard Houlston, Elizabeth Bancroft, Elizabeth Page, Audrey Ardern-Jones, Kelly Kohut, Jennifer Wiggins, Elena Castro, Anita Mitra; North Trent Clinical Genetics Service, Sheffield: Jackie Cook, Oliver Quarrell, Cathryn Bardsley; South West Thames Regional Genetics Service, London: Shirley Hodgson, Sheila Goff, Glen Brice, Lizzie Winchester, Charlotte Eddy, Vishakha Tripathi, Virginia Attard; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton: Diana Eccles,

Anneke Lucassen, Gillian Crawford, Donna McBride, Sarah Smalley; JoEllen Weaver and Dr Betsy Bove; National Cancer Genetics Network UNICANCER Genetic Group, France; GEMO collaborating groups: Coordinating Centres, Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, Centre Léon Bérard, & Equipe Génétique du cancer du sein, Centre de Recherche en Cancérologie de Lyon: Olga Sinilnikova, Sylvie Mazoyer, Francesca Damiola, Laure Barjhoux, Carole Verny-Pierre, Alain Calender, Sophie Giraud, Mélanie Léone; and Service de Génétique Oncologique, Institut Curie, Paris: Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Claude Houdayer, Virginie Moncoutier, Muriel Belotti, Carole Tirapo, Antoine de Pauw; Institut Gustave Roussy, Villejuif: Brigitte Bressac-de-Paillerets, Olivier Caron; Centre Jean Perrin, Clermont-Ferrand: Yves-Jean Bignon, Nancy Uhrhammer; Centre Léon Bérard, Lyon: Christine Lasset, Valérie Bonadona, Sandrine Handallo. Centre François Baclesse, Caen: Agnès Hardouin, Pascaline Berthet; Institut Paoli Calmettes, Marseille: Hagay Sobol, Violaine Bourdon, Tetsuro Noguchi, Audrey Remenieras, François Eisinger; CHU Arnaud-de-Villeneuve, Montpellier: Isabelle Coupier, Pascal Pujol; Centre Oscar Lambret, Lille: Jean-Philippe Peyrat, Joëlle Fournier, Françoise Révillon, Philippe Vennin, Claude Adenis; Hôpital René Huguenin/Institut Curie, St Cloud: Etienne Rouleau, Rosette Lidereau, Liliane Demange, Catherine Nogues; Centre Paul Strauss, Strasbourg: Danièle Muller, Jean-Pierre Fricker; Institut Bergonié, Bordeaux: Emmanuelle Barouk-Simonet, Françoise Bonnet, Virginie Bubien, Nicolas Sevenet, Michel Longy; Institut Claudius Regaud, Toulouse: Christine Toulas, Rosine Guimbaud, Laurence Gladieff, Viviane Feillel; CHU Grenoble: Dominique Leroux, Héléne Dreyfus, Christine Rebschung, Magalie Peysse; CHU Dijon: Fanny Coron, Laurence Faivre; CHU St-Etienne: Fabienne Prieur, Marine Lebrun, Caroline Kientz; Hôtel Dieu Centre Hospitalier, Chambéry: Sandra Fert Ferrer; Centre Antoine Lacassagne, Nice: Marc Fréney; CHU Limoges: Laurence Vénat-Bouvet; CHU Nantes: Capucine Delnatte; CHU Bretonneau, Tours: Isabelle Mortemousque; Groupe Hospitalier Pitié-Salpêtrière, Paris: Florence Coulet, Chrystelle Colas, Florent Soubrier; CHU Vandoeuvre-les-Nancy: Johanna Sokolowska, Myriam Bronner; CHU Besançon: Marie-Agnès Collonge-Rame, Alexandre Damette; Creighton University, Omaha, NE, USA: Henry T Lynch, Carrie L Snyder; technical support of Ilse Coene en Brecht Crombez; Pedro Perez Segura, Atocha Romero, Paula Diaque and families; Drs Kristiina Aittomäki, Carl Blomqvist and Kirsimari Aaltonen, Taru A Muranen and registered nurses Irja Erkkilä and Virpi Palola. HEBON consists of the following collaborating centers: Coordinating center: Netherlands Cancer Institute, Amsterdam: MA Rookus, FBL Hogervorst, FE van Leeuwen, S Verhoef, MK Schmidt, JL de Lange, R Wijnands; Erasmus Medical Center, Rotterdam: JM Collée, AMW van den Ouweland, MJ Hooning, C Seynaeve, CHM van Beurzen, IM Obdeijn; Leiden University Medical Center, the Netherlands: CJ van Asperen, JT Wijnen, RAEM Tollenaar, P Devilee, TCTEF van Cronenburg; Radboud University Nijmegen Medical Center, the Netherlands: CM Kets, AR Mensenkamp; University Medical Center Utrecht, the Netherlands: MGEM Ausems, RB van der Looij; Amsterdam Medical Center: CM Aalfs, TAM van Os; VU University Medical Center, Amsterdam: JJP Gille, Q Waisfisz, HEJ Meijers-Heijboer; University Hospital Maastricht, the Netherlands: EB Gómez-García, MJ Blok; University Medical Center Groningen, the Netherlands: JC Oosterwijk, AH van der Hout, MJ Mourits, GH de Bock; The Netherlands Foundation for the Detection of Hereditary Tumours, Leiden: HF Vasen; The Netherlands Cancer Registry: S Siesling; The Dutch Pathology Registry (PALGA): LIH Overbeek; Hong Kong Sanatorium & Hospital; Hungarian Breast and Ovarian Cancer Study Group members: Janos Papp, Tibor Vaszko, Aniko Bozsik, Timea Pocza, Judit Franko, Maria Balogh, Gabriella Domokos, Judit Ferenczi, Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary, and the clinicians and patients; Oncogenetics Group and the High Risk and Cancer Prevention Unit of the University Hospital Vall d'Hebron led by Dr J Balmaña; ICO Hereditary Cancer Program team led by Dr Gabriel Capella; Dr Martine Dumont, Martine Tranchant. JS is Chairholder of the Canada Research Chair in Oncogenetics. JS and PS were part of the QC and Genotyping coordinating group of iCOGS (BCAC and CIMBA); Drs Ana Peixoto, Catarina Santos, Patrícia Rocha and Pedro Pinto; Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study and the many families who contribute to kConFab; Modifier Study of Quantitative Effects on Disease (MODSQUAD) acknowledges MODSQUAD members Csilla Szabo (National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA); Lenka Foretova and Eva Machackova (Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic); and Michal Zikan, Petr Pohreich and Zdenek Kleibl (Oncogynecologic Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague,

Czech Republic); the NICCC National Familial Cancer Consultation Service team led by Sara Dishon, the lab team led by Dr Flavio Lejbkowitz, and the research field operations team led by Dr Mila Pinchev; Teresa Selander, Nayana Weerasooriya; Kevin Sweet, Caroline Craven, and Michelle O'Connor; The Ohio State University (OSU) Human Genetics Sample Bank; Yip Cheng Har, Nur Aishah Mohd Taib, Phuah Sze Yee, Norhashimah Hassan and all the research nurses, research assistants and doctors involved in the MyBrCa Study; Philip lau, Sng Jen-Hwei and Sharifah Nor Akmal; Meirav comprehensive breast cancer center team at the Sheba Medical Center; Swedish scientists participating as SWE-BRCA collaborators are: from Lund University and University Hospital: Åke Borg, Håkan Olsson, Helena Jernström, Karin Henriksson, Katja Harbst, Maria Soller, Niklas Loman, Ulf Kristoffersson; from Gothenburg Sahlgrenska University Hospital: Anna Öfverholm, Margareta Nordling, Per Karlsson, Zakaria Einbeigi; from Stockholm and Karolinska University Hospital: Anna von Wachenfeldt, Annelie Liljegen, Annika Lindblom, Brita Arver, Gisela Barbany Bustinza, Johanna Rantala; from Umeå University Hospital: Beatrice Melin, Christina Edwinsdotter Ardnor, Monica Emanuelsson; from Uppsala University: Hans Ehrencrona, Maritta Hellström Pigg, Richard Rosenquist; from Linköping University Hospital: Marie Stenmark-Askmal, Sigrun Liedgren; Cecilia Zvocec, Qun Niu, physicians, genetic counselors, research nurses and staff of the Cancer Risk Clinic, and the many families who contribute to our program; Joyce Seldon, MSGC, and Lorna Kwan, MPH; Dr Robert Nussbaum and the following genetic counselors for participant recruitment: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Blanco and Peggy Conrad; Salina Chan; Paul Pharoah, Simon Gayther, Susan Ramus, Carole Pye, Patricia Harrington and Eva Wozniak; Geoffrey Lindeman, Marion Harris, Martin Delatycki of the Victorian Familial Cancer Trials Group; Sarah Sawyer, Rebecca Driessen and Ella Thompson.

Funding statement

The CIMBA data management and analysis are funded through Cancer Research UK grant C12292/A11174. ACA is a Senior Cancer Research UK Research Fellow. Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112: the Genetic Associations and Mechanisms in Oncology (GAME-ON) initiative), the US Department of Defense (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. This work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US government or the BCFR. This work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this article does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US government or the BCFR. This work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US government or the BCFR. BFOCC is partly supported by: Lithuania (BFOCC-LT): Research Council of Lithuania grant LIG-07/2012; Latvia (BFOCC-LV) is partly supported by LSC grant 10.0010.08 and in part by a grant from the ESF 2009/0220/1DP/1.1.1.2.0/09/APIA/VIAA/016 and Liepaja's municipal council. BIDMC is supported by the Breast Cancer Research Foundation. BRCA-gene mutations and breast cancer in South African women (BMBSA) was supported by grants from the Cancer Association of South Africa (CANSA) to Elizabeth J van Rensburg. SLN was partially supported by the Morris and Horowitz Families Endowed Professorship. This work was supported by the NEYE Foundation. The CNIO study was supported by Spanish Association against Cancer (AECC08), RTICC 06/0020/1060 and FISPI2/00070 and Mutua Madrileña Foundation (FMMA). City of Hope Clinical Cancer Genetics Community Network and the Hereditary Cancer Research Registry, supported in part by Award Number

RC4CA153828 (Principal Investigator: J Weitzel) from the National Cancer Institute and the Office of the Director, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funds from Italian citizens who allocated the "5 x 1000" share of their tax payment, according to Italian laws, in support of the Fondazione IRCCS Istituto Nazionale Tumori (to SM), and of IRCCS AOU San Martino, IST Istituto Nazionale per la Ricerca sul Cancro (to LV); Italian Association for Cancer Research (AIRC) to GG; Associazione CAOS-Varese (to MGT). SH is supported by an NHMRC Program Grant (to GCT). GCT is an NHMRC Senior Principal Research Fellow. This research has been cofinanced by the European Union (European Social Fund (ESF)) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF), Research Funding Program of the General Secretariat for Research & Technology: ARISTEIA, investing in knowledge society through the European Social Fund. The DKFZ study was supported by the DKFZ. EMBRACE is supported by Cancer Research UK grants C1287/A10118, C1287/A16563 and C1287/A17523. D Gareth Evans and Fiona Laloo are supported by an NIHR grant to the Biomedical Research Centre, Manchester. The investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Ros Eeles and Elizabeth Bancroft are supported by Cancer Research UK grant C5047/A8385. The authors acknowledge support from The University of Kansas Cancer Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program. AKG was funded by grants 5U01 CA113916, R01 CA140323 from the National Institutes of Health and by the Chancellors Distinguished Chair in Biomedical Sciences Professorship. The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant no 109076, Rita K Schmutzler) and by the Center for Molecular Medicine Cologne (CMMC). The study was supported by the Ligue Nationale Contre le Cancer; the Association "Le cancer du sein, parlons-en!" Award; and the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program. Tom Van Maerken is senior clinical investigator of FWO. This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office and Tissue Bank (CA 27469), the GOG Statistical and Data Center (CA 37517), and GOG's Cancer Prevention and Control Committee (CA 101165). Drs Greene, Mai and Savage were supported by funding from the NCI Intramural Research Program. HCSC was supported by a grant RD12/00369/0006 and 12/00539 from ISCIII (Spain), partially supported by European Regional Development FEDER funds. The HEBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation. The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands Organization of Scientific Research grant NWO 91109024, the Pink Ribbon grant 110005 and the BBMRI grant NWO 184.021.007/CP46. HEBON thanks the registration teams of the Comprehensive Cancer Centre Netherlands and Comprehensive Centre South (together the Netherlands Cancer Registry) and PALGA (Dutch Pathology Registry) for part of the data collection. HRBCP is supported by The Hong Kong Hereditary Breast Cancer Family Registry and the Dr Ellen Li Charitable Foundation, Hong Kong. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745 and OTKA K-112228. ICO: Contract grant sponsor: Asociación Española Contra el Cáncer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of Catalonia. Contract grants ISCIIRETIC RD06/0020/1051, RD12/0036/008, PI10/01422, PI10/00748, PI13/00285 and 2009SGR290. The IHCC was supported by Grant PBZ_KBN_122/P05/2004. The ILUH group was supported by the Icelandic Association "Walking for Breast Cancer Research" and by the Landspítali University Hospital Research Fund. This work was supported by the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program, Canadian Breast Cancer Research Alliance grant 019511 and Ministry of Economic Development, Innovation and Export Trade grant PSR-SIIRI-701. IOVHBOCS is supported by Ministero della Salute and "5 x 1000" Istituto Oncologico Veneto grant. This study was in part supported by Liga Portuguesa Contra o Cancro. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. GCT and ABS are supported by the NHMRC Research

Fellowship scheme. KOHBRA is supported by a grant from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea (1020350). MAYO is supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a US Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341) and a grant from the Breast Cancer Research Foundation. Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation and Export Trade. MODSQUAD was supported by MH CZ - DRO (MMCI, 00209805) and by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101) (to LF), and by Charles University in Prague project UNCE204024 (MZ). MSKCC is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative 1R01 CA149429-01. The research of MH Greene and PL Mai was supported by the Intramural Research Program of the US National Cancer Institute, NIH, and by support services contracts N02-CP-11019-50 and N02-CP-65504 with Westat (Rockville, MD, USA). NICCC is supported by Clalit Health Services in Israel. Some of its activities are supported by the Israel Cancer Association and the Breast Cancer Research Foundation (BCRF), New York. This work has been supported by the Russian Foundation for Basic Research (grant 13-04-92613).

This work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US government or the BCFR. OSUCCG is supported by The Ohio State University Comprehensive Cancer Center. This work was supported by the ITT (Istituto Toscano Tumori) grants 2011–2013; the Ministry of Science, Technology and Innovation, Ministry of Higher Education (UM.C/HIR/MOHE/06); and the Cancer Research Initiatives Foundation. This project was partially funded through a grant by the Israel cancer association and the funding for the Israeli Inherited breast cancer consortium.

SWE-BCRA collaborators are supported by the Swedish Cancer Society. UCHICAGO is supported by NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996, 1U01 CA161032 and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Women's Cancer Research Alliance and the Breast Cancer Research Foundation. OIO is an ACS Clinical Research Professor. Jonsson Comprehensive Cancer Center Foundation; Breast Cancer Research Foundation. UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center. UKFOCR was supported by a project grant from CRUK to Paul Pharoah. National Institutes of Health (NIH) (R01 CA102776 and R01 CA083855; Breast Cancer Research Foundation; Susan G Komen Foundation for the cure, Basser Research Center for BRCA. Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation. The Women's Cancer Program (WCP) at the Samuel Oschin Comprehensive Cancer Institute is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN).

Author details

¹Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ²Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. ³Clinical Genetics Research Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. ⁵Laboratory Medicine Program, University Health Network, Toronto, ON, Canada. ⁶Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada. ⁷Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. ⁸Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia. ⁹Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands. ¹⁰Center for Hereditary Breast and Ovarian Cancer, Medical Faculty, University Hospital Cologne, Cologne, Germany. ¹¹Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany. ¹²Center for Molecular Medicine Cologne (CMMC), University of Cologne, on behalf of the German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC), Cologne, Germany. ¹³Institute for Medical Informatics, Statistics and Epidemiology University of Leipzig, Leipzig, Germany. ¹⁴Center for Molecular

Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.

¹⁵Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, HUS, Finland. ¹⁶Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark. ¹⁷Department of Pathology, Genetic Epidemiology Laboratory, University of Melbourne, Parkville, Australia. ¹⁸Department of Preventive and Predictive Medicine, Unit of Molecular Bases of Genetic Risk and Genetic Testing, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. ¹⁹Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. ²⁰Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ²¹Department of Genetics & Computational Biology, Queensland Institute of Medical Research, Herston, Australia. ²²Department of Medicine and Institute for Human Genetics, University of California, San Francisco, CA, USA. ²³Abramson Cancer Center and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ²⁴University of Texas MD Anderson Cancer Center, Houston, TX, USA. ²⁵Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia. ²⁶Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia. ²⁷Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ²⁸Department of Epidemiology, Cancer Prevention Institute of California, Fremont, CA, USA. ²⁹Department of Epidemiology, Columbia University, New York, NY, USA. ³⁰Fox Chase Cancer Center, Philadelphia, PA, USA. ³¹Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA. ³²Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. ³³Department of Molecular and Regenerative Medicine, Vilnius University Hospital Santariskiu Clinics, Hematology, Oncology and Transfusion Medicine Center, Vilnius, Lithuania. ³⁴State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania. ³⁵Latvian Biomedical Research and Study Centre, Riga, Latvia. ³⁶Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA. ³⁷Department of Genetics, University of Pretoria, Pretoria, South Africa. ³⁸Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ³⁹Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ⁴⁰Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ⁴¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. ⁴²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. ⁴³Human Genetics Group, Spanish National Cancer Centre (CNIO), and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain. ⁴⁴Human Genetics Group and Genotyping Unit, Spanish National Cancer Centre (CNIO), and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain. ⁴⁵Institute of Biology and Molecular Genetics, Universidad de Valladolid (IBGM-UVA), Valladolid, Spain. ⁴⁶Clinical Cancer Genetics, City of Hope (for the City of Hope Clinical Cancer Genetics Community Research Network), Duarte, CA, USA. ⁴⁷Covenant Health Joe Arrington Cancer Research Center, care of City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA. ⁴⁸Kootenai Cancer Center, care of City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA. ⁴⁹FOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. ⁵⁰Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. ⁵¹Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy. ⁵²FOM, Fondazione Istituto FIRC di Oncologia Molecolare and Cogentech Cancer Genetic Test Laboratory, Milan, Italy. ⁵³Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, PN, Italy. ⁵⁴Unit of Hereditary Cancer, IRCCS AOU San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. ⁵⁵Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy. ⁵⁶Ospedale di Circolo e Fondazione Macchi Polo Universitario, Varese, Italy. ⁵⁷Department of Molecular Medicine, University La Sapienza, Rome, Italy. ⁵⁸Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research "Demokritos", Aghia Paraskevi Attikis, Athens, Greece. ⁵⁹Dana-Farber Cancer Institute, Boston, MA, USA. ⁶⁰Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany. ⁶¹Clinical Genetics Department, St Michael's Hospital, Bristol, UK. ⁶²Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, UK. ⁶³Cheshire and Merseyside Clinical Genetics Service, Liverpool Women's NHS Foundation Trust, Liverpool, UK. ⁶⁴Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.

⁶⁵University of Southampton Faculty of Medicine, Southampton University Hospitals NHS Trust, Southampton, UK ⁶⁶Institute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK. ⁶⁷North West Thames Regional Genetics Service, Kennedy-Galton Centre, Harrow, UK. ⁶⁸Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK. ⁶⁹Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, UK. ⁷⁰Yorkshire Regional Genetics Service, Leeds, UK. ⁷¹Leicestershire Clinical Genetics Service, University Hospitals of Leicester NHS Trust, Leicester, UK. ⁷²West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Edgbaston, Birmingham, UK. ⁷³Oxford Regional Genetics Service, Churchill Hospital, Oxford, UK. ⁷⁴Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK. ⁷⁵North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Trust, London, UK. ⁷⁶Academic Unit of Clinical and Molecular Oncology, Trinity College Dublin and St James's Hospital, Dublin, Ireland. ⁷⁷All Wales Medical Genetics Services, University Hospital of Wales, Cardiff, UK. ⁷⁸South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, UK. ⁷⁹Department of Medical Genetics, Belfast Health and Social Care Trust, Centre for Cancer Research & Cell Biology, Queen's University Belfast, Belfast, UK. ⁸⁰Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK. ⁸¹Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospitals, Glasgow, UK. ⁸²Medical Genetics Unit, St George's, University of London, London, UK. ⁸³Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA. ⁸⁴Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. ⁸⁵Department of Gynaecology and Obstetrics, University Munich, Munich, Germany. ⁸⁶University Hospital of Schleswig-Holstein/University Kiel, Kiel, Germany. ⁸⁷Institute of Human Genetics, University Hospital of Schleswig-Holstein, University Kiel, Kiel, Germany. ⁸⁸University Düsseldorf, Düsseldorf, Germany. ⁸⁹University Heidelberg, Heidelberg, Germany. ⁹⁰Hannover Medical School, Hannover, Germany. ⁹¹Institute of Human Genetics, Münster, Germany. ⁹²University Dresden, Dresden, Germany. ⁹³Institute of Medical Genetics and Human Genetics, Charité, Berlin, Germany. ⁹⁴Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany. ⁹⁵Institute of Human Genetics, University Würzburg, Würzburg, Germany. ⁹⁶Department of Tumour Biology, Institut Curie, Paris, France. ⁹⁷Institut Curie, INSERM U830, Paris, France. ⁹⁸Université Paris Descartes, Sorbonne Paris Cité, Paris, France. ⁹⁹Laboratoire d'Oncogénétique, Hôpital René Huguenin, Institut Curie, Saint-Cloud, France. ¹⁰⁰Service de Génétique Clinique Chromosomique et Moléculaire, Centre Hospitalier Universitaire de St Etienne, St Etienne, France. ¹⁰¹INSERM U1052, CNRS UMR5286, Université Lyon, Centre de Recherche en Cancérologie de Lyon, Lyon, France. ¹⁰²GEMO Study: National Cancer Genetics Network, UNICANCER Genetic Group, Paris, France. ¹⁰³Centre de Génétique, CHU Dijon, Université de Bourgogne, Dijon, France. ¹⁰⁴Centre Georges François Leclerc, Dijon, France. ¹⁰⁵Cancer Genetics Unit, INSERM U916, Institut Bergonié, Université de Bordeaux, Bordeaux, France. ¹⁰⁶Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, Centre Léon Bérard, Lyon, France. ¹⁰⁷Université Lyon 1, CNRS UMR5558, Lyon, France. ¹⁰⁸Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, Lyon, France. ¹⁰⁹Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. ¹¹⁰Center for Medical Genetics, Ghent University, Ghent, Belgium. ¹¹¹Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY, USA. ¹¹²ANZGOG Australia, New Zealand Gynaecological Oncology Group, Prince of Wales Hospital, Randwick, Australia. ¹¹³The Ohio State University, Columbus Cancer Council, Columbus, OH, USA. ¹¹⁴Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, USA. ¹¹⁵Molecular Oncology Laboratory, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. ¹¹⁶Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, the Netherlands. ¹¹⁷Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands. ¹¹⁸Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ¹¹⁹Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands. ¹²⁰Department of Genetics, University Medical Center, Groningen University, Groningen, The Netherlands. ¹²¹Department of Human Genetics and Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. ¹²²Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands. ¹²³Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. ¹²⁴Department of Clinical Genetics, Erasmus University Medical Center,

Rotterdam, The Netherlands. ¹²⁵Department of Pathology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands. ¹²⁶Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. ¹²⁷The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), coordinating center: Netherlands Cancer Institute, Amsterdam, The Netherlands. ¹²⁸Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. ¹²⁹Oncogenetics Group, University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona, Barcelona, Spain. ¹³⁰Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain. ¹³¹Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain. ¹³²Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. ¹³³Department of Pathology, Landspítali University Hospital and BMC, Faculty of Medicine, University of Iceland, Reykjavik, Iceland. ¹³⁴Laboratoire de diagnostic génétique et Service d'Onco-hématologie, Hopitaux Universitaires de Strasbourg, CHRU Nouvel Hôpital Civil, Strasbourg, France. ¹³⁵Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec City, QC, Canada. ¹³⁶Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV, IRCCS, Padua, Italy. ¹³⁷Department of Genetics, Portuguese Oncology Institute, Porto, Portugal. ¹³⁸ConFab: Kathleen Cuninghame Consortium for Research into Familial Breast Cancer, Peter MacCallum Cancer Center, Melbourne, Australia. ¹³⁹Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA. ¹⁴⁰Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. ¹⁴¹National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. ¹⁴²Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. ¹⁴³Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. ¹⁴⁴Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA. ¹⁴⁵National Cancer Institute, National Institutes of Health, Rockville, MD, USA. ¹⁴⁶Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B Rappaport Faculty of Medicine, Haifa, Israel. ¹⁴⁷NN Petrov Institute of Oncology, St Petersburg, Russia. ¹⁴⁸Ontario Cancer Genetics Network: Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Cancer Care Ontario, Toronto, ON, Canada. ¹⁴⁹Division of Human Cancer Genetics, Departments of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. ¹⁵⁰Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark. ¹⁵¹Section of Molecular Diagnostics, Department of Biochemistry, Aalborg University Hospital, Aalborg, Denmark. ¹⁵²Department of Clinical Genetics, Aarhus University Hospital, Aarhus N, Denmark. ¹⁵³Section of Genetic Oncology, Department of Laboratory Medicine, University and University Hospital of Pisa, Pisa, Italy. ¹⁵⁴Sheba Medical Center, Tel Aviv, Israel. ¹⁵⁵Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. ¹⁵⁶Department of Oncology, Karolinska University Hospital, Stockholm, Sweden. ¹⁵⁷Department of Oncology, Lund University Hospital, Lund, Sweden. ¹⁵⁸Department of Oncology, Lund University, Lund, Sweden. ¹⁵⁹Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. ¹⁶⁰Department of Clinical Genetics, Lund University Hospital, Lund, Sweden. ¹⁶¹Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, IL, USA. ¹⁶²Department of Clinical Genetics, Lund University Hospital, Lund, Sweden. ¹⁶³5841 South Maryland Avenue, MC 2115 Chicago, IL, USA.

Received: 11 June 2014 Accepted: 2 December 2014

Published online: 31 December 2014

References

- Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiol Biomarkers Prev.* 2012;21:134–47.
- Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. *J Natl Cancer Inst.* 1998;90:1138–45.
- Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. *Clin Cancer Res.* 2005;11:5175–80.

4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A*. 2003;100:8418–23.
5. Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. *Am J Surg Pathol*. 2007;31:121–8.
6. Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchoff T, McGuffog L, et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genet*. 2013;9:e1003173.
7. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genet*. 2013;9:e1003212.
8. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat Genet*. 2013;45:353–61. 361e351–352.
9. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nat Genet*. 2013;45:392–8. 398e391–392.
10. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet*. 2013;45:371–84. 384e371–372.
11. Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. *Hum Mol Genet*. 2012;21:5373–84.
12. Stevens KN, Fredericksen Z, Vachon CM, Wang X, Margolin S, Lindblom A, et al. 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. *Cancer Res*. 2012;72:1795–803.
13. Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, et al. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Res*. 2012;14:R33.
14. Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, et al. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev*. 2012;21:645–57.
15. Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Res*. 2011;13:R110.
16. French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *Am J Hum Genet*. 2013;92:489–503.
17. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE, et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Res*. 2007;9:104.
18. Percy C, Vanholten V, Muir G, Sobin L. New International Classification of Diseases for Oncology (Icd-O, 2nd Edition) and the Neoplasm Chapter of the 10th Revision of the International Classification of Diseases (Icd-10). *Laboratory Investigation*. 1990;62:A113.
19. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, et al. RAD51 135G > C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studie. *Am J Hum Genet*. 2007;81:1186–200.
20. Barnes DR, Lee A, Investigators E, kConFab I, Easton DF, Antoniou AC. Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. *Genet Epidemiol*. 2012;36:274–91.
21. Gaffey MJ, Mills SE, Frierson Jr HF, Zarbo RJ, Boyd JC, Simpson JF, et al. Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis. *Mod Pathol*. 1995;8:31–8.
22. Rigaud C, Theobald S, Noel P, Badreddine J, Barlier C, Delobelle A, et al. Medullary carcinoma of the breast: A multicenter study of its diagnostic consistency. *Arch Pathol Lab Med*. 1993;117:1005–8.
23. Lange K, Weeks D, Boehnke M. Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE. *Genet Epidemiol*. 1988;5:471–2.
24. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol Bull*. 1979;86:420–8.
25. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet*. 2008;40:703–6.
26. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet*. 2015;47:164–71.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Kuchenbaecker, KB; Neuhausen, SL; Robson, M; Barrowdale, D; McGuffog, L; Mulligan, AM; Andrulic, IL; Spurdle, AB; Schmidt, MK; Schmutzler, RK; Engel, C; Wappenschmidt, B; Nevanlinna, H; Thomassen, M; Southey, M; Radice, P; Ramus, SJ; Domchek, SM; Nathanson, KL; Lee, A; Healey, S; Nussbaum, RL; Rebbeck, TR; Arun, BK; James, P; Karlan, BY; Lester, J; Cass, I; Terry, MB; Daly, MB; Goldgar, DE; Buys, SS; Janavicius, R; Tihomirova, L; Tung, N; Dorfling, CM; van Rensburg, EJ; Steele, L; Hansen, TVO; Ejlertsen, B; Gerdes, A-M; Nielsen, FC; Dennis, J; Cunningham, J; Hart, S; Slager, S; Osorio, A; Benitez, J; Duran, M; Weitzel, JN; Tafur, I; Hander, M; Peterlongo, P; Manoukian, S; Peissel, B; Roversi, G; Scuvera, G; Bonanni, B; Mariani, P; Volorio, S; Dolcetti, R; Varesco, L; Papi, L; Tibiletti, MG; Giannini, G; Fostira, F; Konstantopoulou, I; Garber, J; Hamann, U; Donaldson, A; Brewer, C; Foo, C; Evans, DG; Frost, D; Eccles, D; Douglas, F; Brady, A; Cook, J; Tischkowitz, M; Adlard, J; Barwell, J; Ong, K-R; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Rogers, MT; Porteous, ME; Morrison, PJ; Platte, R; Eeles, R; Davidson, R; Hodgson, S; Ellis, S; Godwin, AK; Rhiem, K; Meindl, A; Ditsch, N; Arnold, N; Plendl, H; Niederacher, D; Sutter, C; Steinemann, D; Bogdanova-Markov, N; Kast, K; Varon-Mateeva, R; Wang-Gohrke, S; Gehrig, A; Markiefka, B; Buecher, B; Lefol, C; Stoppa-Lyonnet, D; Rouleau, E; Prieur, F; Damiola, F; Barjhoux, L; Faivre, L; Longy, M; Sevenet, N; Sinilnikova, OM; Mazoyer, S; Bonadona, V; Caux-Moncoutier, V; Isaacs, C; Van Maerken, T; Claes, K; Piedmonte, M; Andrews, L; Hays, J; Rodriguez, GC; Caldes, T; de la Hoya, M; Khan, S; Hogervorst, FBL; Aalfs, CM; de Lange, JL; Meijers-Heijboer, HEJ; van der Hout, AH; Wijnen, JT; van Roozendaal, KEP; Mensenkamp, AR; van den Ouweland, AMW; van Deurzen, CHM; van der Luijt, RB; Olah, E; Diez, O; Lazaro, C; Blanco, I; Teule, A; Menendez, M; Jakubowska, A; Lubinski, J; Cybulski, C; Gronwald, J; Jaworska-Bieniek, K; Durda, K; Arason, A; Maugard, C; Soucy, P; Montagna, M; Agata, S; Teixeira, MR; Olswold, C; Lindor, N; Pankratz, VS; Hallberg, E; Wang, X; Szabo, CI; Vijai, J; Jacobs, L; Corines, M; Lincoln, A; Berger, A; Fink-Retter, A; Singer, CF; Rappaport, C; Kaulich, DG; Pfeiler, G; Tea, M-K; Phelan, CM; Mai, PL; Greene, MH; Rennert, G; Imyanitov, EN; Glendon, G; Toland, AE; Bojesen, A; Pedersen, IS; Jensen, UB; Caligo, MA; Friedman, E; Berger, R; Laitman, Y; Rantala, J; Arver, B; Loman, N; Borg, A; Ehrencrona, H; Olopade, OI; Simard, J; Easton, DF; Chenevix-Trench, G; Offit, K; Couch, FJ; Antoniou, AC